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ABSTRACT 
Sarah Ruth Hoffman: Combined oral contraceptive utilization and uterine fibroid incidence and prevalence 
in the Study of Environment, Lifestyle, and Fibroids (SELF)  
(Under the direction of Jennifer S. Smith) 
 
 Estrogen and progesterone play complex, interrelated roles in fibroid tumor development. 
Hormonal contraceptives are composed of progestin (synthetic progesterone) and may also include 
estrogen. The most common form of hormonal contraception used in the United States is combined oral 
contraception. To date, existing published literature regarding the association between combined oral 
contraceptives (COC) use and uterine fibroid development have yielded mixed findings, limited by lack of 
baseline ultrasounds that could establish temporality, and often restricted to outcome ascertainment 
among symptomatic, mostly white, women seeking treatment.  
The Study of Environment, Lifestyle, and Fibroids (SELF) was the first prospective, ultrasound-
based study of risk factors for uterine fibroids. SELF consists of 1,696 young (23-34 years), black women 
living in the Detroit, Michigan area in 2010-2017. We examined associations between different levels of 
COC use and the 40-month cumulative risk of uterine fibroids, and baseline fibroid prevalence. 
Specifically, we examined ever use of COCs, and age at first use, duration of use, and time since last use 
among ever COC users. Inverse probability weights were constructed for all exposures, and censoring. 
Standardized mortality ratio weights were constructed for ever COC use. At ~40-months’ follow-up, we 
observed a possible protective association between ever use of COCs and cumulative fibroid incidence 
among women who were without fibroids at study enrollment (wRR: 0.78; 95% CI: 0.60, 1.00). When 
restricting the “Never” comparator group to ever hormonal contraceptive (HC) users, the observed 
association between COC use and fibroid incidence was attenuated (wRR: 0.92; 95% CI: 0.60, 1.40). The 
protective association re-emerged when restricting the “Never” group to women with no history of HC use 
(wRR: 0.72; 95% CI: 0.51, 1.01). No associations were found between fibroid prevalence or incidence 
and the remaining exposures. It remains unclear how differing levels of COC use among ever COC users 
might confer differing levels of protection or harm, if any.   
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CHAPTER ONE: STATEMENT OF SPECIFIC AIMS 
More than 1 billion U.S. dollars are spent each year to treat uterine fibroids.1 In the U.S., black 
women experience greater risk of, and a 10-year earlier onset of, fibroids than white women, and their 
fibroids are more severe.2 At least 80% of black women will develop uterine fibroids in their 
lifetime.3 Fibroid symptoms include pelvic pressure, pain, and heavy menstrual bleeding leading to iron 
deficiency anemia.4 Fibroids can cause infertility and obstetric complications, and may be associated with 
preterm delivery.4,5 Unfortunately, there is currently no known approach to prevent or permanently cure 
uterine fibroids while leaving the uterus and fertility intact.  
Estrogen and progesterone have complex, interrelated roles in fibroid tumor development.6,7 
Progesterone appears to cause fibroid growth, and estrogen increases availability of progesterone 
receptors.7 Oral contraceptives (OCs) are generally composed of both estrogen and progestin (synthetic 
progestogen).8 Exposure to OCs is widespread in the U.S.9–11 Among sexually experienced black women 
aged 15-44, 80% have used OCs in their lifetime.9  
The data on oral contraceptives and fibroid risk have been mixed, with some studies showing a 
detrimental association if taken early in life,12,13 and others demonstrating a protective association14–16 or 
no associaion at all.17–20 Studies of OC use and fibroid development to date have lacked baseline fibroid 
assessments and are unable to establish temporality of OC use and fibroid occurrence. Furthermore, 
studies of OC use and fibroid development are limited to fibroid assessment by clinical recognition; i.e., 
only women who sought treatment for fibroid symptoms and who had access to care were screened. 
Thus, the resulting associations may have been biased by factors related to clinical or surgical detection, 
including perception of symptoms and access to medical treatment.2   
This study addressed these concerns by leveraging existing prospective data from the Study of 
Environment, Lifestyle & Fibroids (SELF). SELF consists of 1,696 young (23-34 years), black women 
living in the Detroit, Michigan area in 2010-2017. SELF was designed specifically for the study of the 
effect of vitamin D on the risk of uterine fibroids.2,21,22 SELF performs baseline and follow-up 
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ultrasounds in all study participants, not just those with symptoms. Study retention rate was high at >85% 
for the 40-month follow-up.  
Specifically, we aimed to: 
Aim 1: Describe the patterns of and reasons for hormonal contraceptive use prior to and at 
enrollment among women enrolled in SELF, including the duration of and time since last use of 
OCs. Switching contraceptive methods is common.9,23,24 However, no data are published on lifetime 
patterns of hormonal contraceptive use among U.S. black women 24  Contraceptive biographies24 were 
constructed for each participant. We described the distribution of HC utilization by HC type for HCs ever 
used and currently in use at enrollment. We also report number of HC types ever used, first HC type 
used, age of first HC use and total duration of HC use in years. For each HC type (e.g., COC, patch, ring, 
shot, H-IUD, mini-pill, and implant) we report age at first use, years since menarche of first use, total 
months used, and reasons for using (e.g., birth control, menstrual problems). Annual initiation rates were 
plotted, and compared to regulatory approval timelines. We constructed Sankey diagrams to depict HC 
sequences of use, and plotted cumulative incidence curves for menarche and HC initiation. Knowledge of 
these patterns provided meaningful context to the findings from the following aim.  
Aim 2: Examine the associations between different levels of combined oral contraceptive 
(COC) use and the 40-month cumulative risk of uterine fibroids, and baseline fibroid prevalence. 
Women were counted as having uterine fibroids if they had one or more lesions of 0.5 cm maximum 
diameter or larger that could be visualized in all three planes.25 Ten percent of SELF participants without 
fibroids at baseline had fibroids detected at the 20-month follow-up.2 Ever use and age at first use of 
COCs were analyzed as dichotomous variables. Age at first use was dichotomized as less than 17 years 
and 17 years or older, based on findings from prior literature.12,13,26 Cumulative lifetime exposure (duration 
of use) and time since last use were analyzed as ordinal variables, to allow for comparison to findings of 
previous studies. Pregnancy and hormonal contraceptive use during follow-up were taken into account in 
sensitivity analyses. Risk and prevalence ratios were calculated comparing each level of COC to the 
lowest level of use.  
This research addressed the longstanding question of whether COC use is associated with fibroid 
development using a novel cohort created specifically for prospective studies of fibroid incidence and 
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growth. Temporality was established and common sources of bias in the study of COCs and fibroid risk 
were addressed.2,27 
Results of this study estimated the association between estrogen-containing oral contraception 
and fibroid incidence and prevalence. The findings from these analyses contribute to the evidence base 
for oral contraceptive safety and effectiveness, allowing providers and patients to make better, evidence-
based decisions regarding oral contraception in young women.   
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CHAPTER TWO: INTRODUCTION 
Uterine Fibroids 
Uterine fibroids are prevalent, costly, and affect black women disproportionately. Uterine 
fibroids are found in 70 to 80% of reproductive-age women in the U.S.3 Clinically relevant leiomyomas 
(i.e., fibroids requiring treatment) are found in 10-50% of women, depending on race and age (Figure 
2.1).3  Incidence of symptomatic fibroids generally increases with age and declines after menopause.6  
Black women are three times as likely as white women to develop fibroids over a 4 year time-
period, even after adjustment for many other factors.28 Fibroids in black women tend to occur earlier in life 
than in white women, and are often more severe.29,30 As a result, black women are 6.8 times as likely as 
white women to undergo uterine fibroid removal surgery (myomectomy).31  
Fibroid symptoms 
include pelvic pressure, 
pain, and heavy menstrual 
bleeding leading to iron 
deficiency anemia.4  
Fibroids can cause 
infertility and obstetric 
complications, and are 
strongly associated with 
preterm delivery.4,5 
Between 10% and 30% of women with uterine fibroids will experience complications during pregnancy.5  
Fibroids can grow to be so large that they mimic the uterine volume and pressure of pregnancy. 
Clinicians often refer to fibroid size as if they were discussing a gravid uterus (i.e., “18-week myomatous 
Figure 2.1. Race and age specific prevalence of symptomatic uterine 



























uterus”). A 20-week size uterus is not uncommon among non-pregnant women with fibroids.32 The pelvic 
pressure associated with these fibroids can cause bladder and bowel dysfunction.4  
Fibroid symptoms cause substantial impairment in health-related quality of life and create fear, 
anxiety, and depression for women with the disease.33,34 Patients also report that their symptoms are a 
source of financial burden.33 Women with fibroids incur higher healthcare costs than patients without 
fibroids.35  
More than $1 billion U.S. dollars are spent each year to treat uterine fibroids.1 Fibroid treatment 
can be quite costly. In the 2003-2010 MarketScan Commercial Claims and Encounters database, the 
average cost for a myomectomy was $15,459, while mean cost for magnetic resonance guided focused 
ultrasound (MRgFUS) was $15,249, and the mean cost for uterine artery embolization (UAE) was 
$18,653.36 Fibroid treatments that reverse infertility must often be repeated, for the fibroids often return, 
adding to the financial burden of this disease.37,38 These costs do not incorporate loss of income during 
procedure and recovery time.  
The financial burden of uterine fibroids (which are more common among black women) is a 
source of unjust financial burden on black families. Among women with symptomatic fibroids, black 
women disproportionately report having inadequate health insurance coverage or no coverage at all to 
treat their fibroids.39 Even with health insurance that offers to cover 80% of the cost of care, fibroid 
removal procedures can be out of reach financially; 20% of the aforementioned cost for a myomectomy 
amounts to just over $3,000. Thus the coinsurance for a single treatment amounts to more than 8% of the 
annual median household income of a black family living in the U.S.36,40  
Unfortunately, there is currently no known way to prevent or permanently cure uterine fibroids 
while leaving the uterus and fertility intact. If oral contraceptives decrease the risk of uterine fibroids or 
shrink existing fibroids, it could help address the unjust emotional, physical, and financial burdens of this 
disease. 
Oral Contraceptives 
Oral contraceptives are the most widely used reversible contraception in the United 
States. The use of hormonal contraceptive methods in the U.S. has increased since the 1990s and 
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continues to rise.10,41 According to the 2006-2010 National Survey of Family Growth (NSFG), 62% of 
reproductive age women are using contraception, and hormonal contraception is the most common type 
used.41 Of women using a contraceptive method in the 2011-2013 NSFG, 45% were using a hormonal 
method as compared to up to 39% in 2002.10  
Oral 
contraception is the 
most common type 
of contraceptive 




exposed to oral 
contraceptives at 
some point in their 
lives.9 Repeated 
surveys reveal that 82% of sexually active women have ever used oral contraception, a figure that 
remained stable from 1995 through 2010. This is despite the introduction of other effective contraceptives 
over the same time period.9 Among black women specifically, 78% of sexually experienced women have 
used oral contraception (Figure 2.2).9 According to the 2006-2010 NSFG, 50% of women under age 25 
are currently using oral contraception.9 
A variety of hormonal contraceptive routes of administration are available in the U.S.: oral 
contraceptives, intrauterine devices (IUDs), transdermal patches, vaginal rings, implants, and injectables. 
The patch and the ring contain both estrogen and progestin.42 Hormonal implants, IUDs, and injectables 
contain only progestin.43 Oral contraceptives almost always contain both hormones, but are also available 
in progestin-only form.42,44  
Switching contraceptive routes is common.9,23 According to the 2006-2010 NSFG, 78% of women 
aged 15-44 who have ever had sex have tried 3 or more different contraceptive methods, and 29% have 
Figure 2.2. Percentage of sexually experienced women aged 15–44 who have 
ever used oral contraceptive pills versus other hormonal methods, by 
race/ethnicity, in the United States, 2006–2010. Data are from the National 
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tried 5 or more methods. Black women had the highest proportion of those who had ever used a 
hormonal method other than oral contraception (44%; Figure 2.2).9 
Many women use oral contraceptives for reasons other than pregnancy prevention. It is estimated 
that more than 1.5 million women (14% of pill users) use oral contraceptives for noncontraceptive 
purposes only. In fact, nearly 1 in 10 women who have never had sex use oral contraception, most 
commonly for menstrual pain and regulation.11 Of all current pill users in the 2006-2008 NSFG, 58% of 
oral contraceptive users used oral contraceptives for at least one reason other than pregnancy 
prevention. Cramps and menstrual pain, menstrual regulation, and acne were the most common 
noncontraceptive reasons for which women used oral contraception. About 50% of women who were 
currently using oral contraception used it for more than one reason.11 Menstrual pain and irregularity are 
common symptoms of uterine fibroids. It is possible that oral contraceptives are used by many women to 
alleviate symptoms of undiagnosed uterine fibroids. 
There is evidence 
that oral contraceptive 
exposure reduces fibroid 
tumor development. Uterine 
fibroids are influenced by 
steroid hormones, primarily 
estrogen and progesterone.6,7 
Estrogen and progesterone 
have complex, interrelated 
roles in fibroid tumor 
development. Progesterone is necessary for the development of fibroid cells, and estrogen increases the 
availability of progesterone receptors.7 There is no documented case of uterine fibroid(s) before puberty, 
and incidence declines (along with estrogen and progesterone) after menopause.7 Despite the elevation 
of estrogen and progesterone during pregnancy, parity is associated with a reduced risk of uterine 
fibroids.7,45 There is no firmly established reason for this paradox. A similar paradox has also been 
observed for hormonal contraceptives, and has yet to be confirmed or explained.7  
Figure 2.3. “Diagrammatic representation of the roles of estrogen and 
progesterone in the pathogenesis of uterine fibroids.” ECM: 
extracellular matrix. Reis et al. (2015)7 
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Overall, the exact mechanisms of uterine fibroid development remain unclear, and have been 
described as “enigmatic”.46 It is still unknown whether the cells from which fibroids arise are stem cells or 
differentiated myometrial cells.7 Estrogen and progesterone could influence the transformation of stem 
cells into fibroid cells, exert some effect on already differentiated myometrial cells, or both (Fig. 3). 
Interestingly, current use of an estrogen-containing contraceptive is associated with an increase 
in serum vitamin D levels.21 Vitamin D is significantly lower in women with fibroids than in healthy 
controls.47 There is a strong dose-response relationship between low serum vitamin D and uterine fibroid 
severity.47  Thus it is possible that some of the effect of OCs on fibroids might be related to their effect on 
vitamin D levels.  
Oral contraceptives, with few exceptions, are composed of both estrogen and progestin (synthetic 
progestogen that binds to progesterone receptors).8 Compared to women who have never used oral 
contraception, women who have ever taken oral contraception appear to be less likely to develop uterine 
fibroids, even after advanced modeling to control for confounding by other factors.13,14,16,48 Additional 
evidence suggests that longer duration of oral contraceptive use may also be protective against 
fibroids.13–16,49 These studies enrolled exclusively15 or mostly13,16,19,20,26,48 non-black participants and 
examined only clinically diagnosed leiomyomas. 
A recent cross-sectional analysis of SELF data found a strong, protective association between 
ever use of injectable progestin (widely known as Depo-Provera) and the presence of uterine fibroids at 
study baseline.50 This protective association was seen even among women who had not used injectable 
progestin for several years. Furthermore, the higher a woman’s cumulative lifetime exposure to injectable 
progestin, the lower her chance of having a fibroid.50 The finding that injectable progestin is protective 
against uterine fibroids is supported by previous findings.12,48 One study48 found a protective association 
for injectable progestin lasting for more than 10 years after the final dose. 
Innovation 
This study was able to capture a higher proportion of fibroid cases than previous studies 
could. With the exception of one study49 which screened women for reproductive outcomes after a dioxin 
releasing chemical plant explosion in 1976, previous studies of oral contraceptive use and fibroid 
9 
development were limited to clinical or surgical recognition of fibroids. In other words, results may have 
been biased by factors related to clinical or surgical detection, including perception of symptoms and 
access to medical treatment.2 For instance, oral contraceptives might mask fibroid symptoms, preventing 
women from seeking diagnosis. This would make oral contraceptives appear protective when they are 
not. SELF addresses this potential bias by performing ultrasounds in all women, not just women with 
symptoms.  
The 1997-2001 Black Women’s Health Study (BWHS)12 assessed the association between self-
reported hormonal contraceptive use and self-reported clinical or surgical diagnosis of uterine fibroids. 
About 10% of participants reported a diagnosis of fibroids during approximately 40-months of follow-up. In 
our cohort (SELF), the same incidence (10%) was found in 20-months of follow-up. Both cohorts are 
composed entirely of black women. The BWHS included an older cohort than SELF (median age of 34 
years with an IQR of 29-40), as SELF only enrolled participants aged 23-34 years at recruitment. Given 
that fibroids tend to be diagnosed in older women, we would expect the BWHS cohort to have a higher 
rate of fibroid incidence, not lower.6,28 This finding could be due to the fact that SELF does not require 
women to seek medical treatment in order to be screened for fibroids. SELF performs fibroid 
screening for all participants at regular intervals regardless of the presence or absence of symptoms. 
Because of this, SELF data captures a higher proportion of fibroid cases than previous studies. 
This study was able to verify that oral contraceptive exposure occurred prior to the 
appearance of fibroids. The temporal relationship between oral contraceptive use and fibroid 
development in existing literature is unclear. Oral contraceptives can mask fibroid symptoms by reducing 
heavy menstrual bleeding, pain, or irregularity. Women whose fibroids are small or asymptomatic at the 
time of oral contraceptive initiation may go undiagnosed. Previous studies were unable to assess fibroid 
status prior to oral contraceptive exposure. Thus, it is unknown how many women already had fibroids 
before they began taking oral contraceptives. This study used baseline ultrasound to identify women with 
preexisting fibroids. The incidence of fibroid development among women without fibroids at the start of 
the study was measured. This study was able to verify that oral contraceptive exposure occurred prior to 
the appearance of fibroids. Because it can establish temporality in this way, this study was able to more 
10 
clearly delineate the relationship between oral contraceptive use and fibroid development than prior 
studies could.  
Contraceptive biographies24 for each study participant were constructed. Switching 
contraceptive methods is common.9,23,24 Despite this fact, there have been no published reports of lifetime 
patterns of hormonal contraceptive use among black women living in the U.S.24 Aim 1 described the 
patterns of and reasons for hormonal contraceptive use in the SELF cohort. Knowledge of these patterns 
in our cohort was necessary for the completion of Aim 2, and offered meaningful context to those findings. 
Furthermore, the completion of this aim serves as an example for future studies of contraceptive 
sequences of use across the lifespan. 
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CHAPTER 3: CRITICAL REVIEW OF THE LITERATURE 
Pathogenesis of Uterine Fibroids and the Potential Role of Hormonal Contraception 
Fibroids consist of multiple, clonal (cells that share a common ancestry) cell types: smooth 
muscle cells, vascular smooth muscle cells, fibroblasts, and fibroid-associated fibroblasts.51 Fibroblasts 
are known to be important in wound healing, and are responsible for the wealth of extracellular matrix 
(ECM) found in fibroid tumors. Fibroblasts are most critical to the pathophysiology of fibroid disease. All 
four of these clonal cell types originate from fibroid progenitor cells.51  
Hormonal contraceptives may influence fibroid development in at least three different places: (1) 
the transformation of myometrial stem cells into fibroid progenitor cells, (2) the differentiation of fibroid 
progenitor cells into preclinical fibroids, (3) the proliferation of fibroid cells into clinically relevant disease.51  
 
Myometrial stem cells → Fibroid progenitor cells → Preclinical fibroids → Clinically relevant disease 
 
First arrow: It is not well understood how or why myometrial stem cells transform into fibroid 
progenitor cells, but sex steroid hormones appear to play an important part.51 Myometrial stem cells 
require sex steroid hormones for their growth, and yet lack the receptors for these hormones.51 The 
mechanism for their growth and subsequent transformation is thought to involve paracrine (cell-to-cell) 
signaling mediated by the Wnt/β-catenin pathway, estrogen, and progesterone.51 If the steroid hormones 
from hormonal contraceptives reach the uterus via circulation, they may contribute to the paracrine 
signaling mechanism by which fibroid progenitor cells develop. If these cells persist, it may explain why 
exposure to oral contraceptives at an early age has been associated with later fibroid development.12,13  
Second arrow: Fibroid progenitor cells differentiate into the four cell types comprising fibroid 
tumors: smooth muscle cells, vascular smooth muscle cells, fibroblasts, and fibroid-associated 
fibroblasts.51 The different fibroid cell types exhibit differential expression of various genes, including 
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progesterone receptor genes.51 The heterogeneity of fibroid biology and clinical presentation are at least 
partially explained by these differences in gene profiles. The expression of these genes is influenced by 
the hormones involved in the menstrual cycle, mainly estrogen and progesterone.51 Thus, it is plausible 
that circulating sex steroid hormones from oral contraceptives could influence gene expression in a way 
that influences fibroid cell differentiation. 
Third arrow: Fibroid cells contain both estrogen and progesterone receptors.7 Progesterone is 
thought to be the primary regulator* of fibroid growth, with estrogen supporting this function by increasing 
progesterone receptor expression in fibroid cells.7 Oral contraceptive use has been associated with 
potentially long-lasting or irreversible changes in estrogen receptor expression in macrophages 
(increased estrogen receptor α and decreased estrogen receptor β);52 hence, it is plausible that oral 
contraceptives induce similarly lasting changes in progesterone and/or estrogen receptor expression in 
the cells of the uterus, including preclinical fibroid cells.  
*Concerning progesterone, while laboratory studies demonstrate that progesterone promotes 
fibroid growth, epidemiological studies of the effects of pregnancy and synthetic progesterone use 
suggest something entirely different.51 The role of progesterone is likely complex and interdependent with 
other pathways.51 
Pharmacology of Oral Contraceptives 
Oral contraceptive pills contain synthetic progesterone (progestin), and are available with and 
without estrogen. Estrogen-containing oral contraceptives are commonly referred to as “combined oral 
contraceptives” (COCs). Most oral contraceptives on the market are COCs. COCs may be monophasic, 
biphasic, or triphasic. Monophasic pills deliver a stable dose of progesterone and estrogen throughout the 
menstrual cycle. Biphasic or triphasic pills alter the dose of estrogen and/or progestin at specific time 
points in the menstrual cycle.  
The most common form of estrogen in COCs is ethinyl estradiol . Estradiol valerate and 
mestranol are also available (Table 3.1). In contrast, there are over eight types of synthetic progesterone 
(progestin) on the oral contraceptive market (Table 3.1). Progestins are grouped into generational classes 
and vary in androgenic, estrogenic,53and progestogenic effects (i.e., varying affinities for binding to 
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androgen, estrogen, and progesterone receptors). These varying affinities coupled with differences in 
dosage may produce varying effects on uterine fibroid development (see Aim 2 literature review). 
Slightly estrogenic progestins include norethindrone, norenthindrone acetate, and ethynodiol 
diacetate.54 Androgenic progestins include medroxyprogesterone acetate (MPA), norethindrone, 
norenthindrone acetate, and ethynodiol diacetate.54 These four drugs also possess antiestrogenic 
properties.54 Norethindrone and norethindrone acetate are first-generation progestins with low 
progestational and estrogenic qualities.55 These progestins are less androgenic than second-generation 
progestins and more androgenic than later generation progestins.55 In contrast, norgestrel (also first 
generation) has strong antiestrogen and androgenic effects.55 At present day, the most widely prescribed 
progestin is levonorgestrel, a second-generation progestin with high progestational and androgenic 
activity.55 A complete summary of all currently available progestins in terms of their affinities for androgen, 





Table 3.1. Compounds used in commercially available hormonal contraceptives in the U.S.  
Compound Oral Injectable Implant Patch Ring IUD Brand Names 
Progestin  
Generation 
Estrogens         
estradiol valerate x      Natazia  
ethinylestradiol x   x x  Yasmin, Seasonale, Ortho Tri-Cyclen  
mestranol x           Norinyl   
Progestins         
MPA x x     Depo-Provera First 
norethindrone x      Femcon Fe, Dasetta, Norinyl, Camila First 
etynodiol diacetate x      Demulen, Zovia First 
norgestrel x      Cryselle, Ovrette First 
norethindrone acetate x      Aygestin First 
levonorgestrel x  x   x Seasonale, Mirena, Plan B, Norplant Second 
norgestimate x      Ortho Tri-Cyclen Third 
desogestrel x      Desogen, Ortho-Cept Third 
etonogestrel   x  x  NuvaRing, Implanon Third 
norelgestromin    x   Ortho Evra Third 
drospirenone x           Beyaz, Yasmin Fourth 







Aim 1: Women’s Reasons for and Patterns of Hormonal Contraceptive Use 
Aim 1: Describe the patterns of and reasons for hormonal contraceptive use [prior to and at 
enrollment] among women enrolled in SELF, including the duration of and time since last use of OCs. 
While there are many published works regarding women’s reasons for discontinuing hormonal 
contraceptives, studies of reasons for initiating use appear relatively scarce. A broad literature search 
revealed a single report, out of the Guttmacher Institute, using nationally representative data from the 
2006-2008 National Survey of Family Growth (NSFG). The NSFG contains contraceptive history with 
dates of use for the four years prior to the interview date, and ever/never use for each type of 
contraception.24 Data were not stratified by race or fibroid status, but do provide a national-level look into 
why women use hormonal contraceptives.  
Birth control was the most commonly cited reason for using oral contraceptives in NSFG.11 Of 
women using oral contraception for non-contraceptive reasons (alone or in addition to birth control as a 
reason), menstrual pain and menstrual regulation were the leading causes for use, followed by acne. 
When data were stratified by age group, non-contraceptive reasons were the leading indication for oral 
contraceptive use in 15-19 year olds, with menstrual pain as the most common reason for use. While 
~49% of U.S. women used oral contraception for more than one reason, fourteen percent of users (more 
than 1.5 million women) used the pill for noncontraceptive purposes only.  
No published data were found regarding lifetime patterns of hormonal contraceptive use.  
Aim 2: Oral Contraceptives and Fibroid Incidence 
Aim 2: Examine the associations between different levels of combined oral contraceptive (COC) 
use and the 40-month cumulative risk of uterine fibroids, and baseline fibroid prevalence. 
For Aim 2, a systematic search of the literature was performed during the summer of 2016 and 
updated in January 2018.  PubMed was searched with the following algorithm: (uterine fibroid[title] OR 
uterine fibroids[title] OR leiomyoma[title] OR leiomyomata[title]) AND (("contraception"[MeSH Terms] OR 
"contraception"[All Fields]) OR ("contraceptive agents"[Pharmacological Action] OR "contraceptive 
devices"[MeSH Terms] OR ("contraceptive"[All Fields] AND "devices"[All Fields]) OR "contraceptive 
devices"[All Fields] OR "contraceptive"[All Fields] OR "contraceptive agents"[MeSH Terms] OR 
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("contraceptive"[All Fields] AND "agents"[All Fields]) OR "contraceptive agents"[All Fields]) OR 
("contraceptive agents"[Pharmacological Action] OR "contraceptive agents"[MeSH Terms] OR 
("contraceptive"[All Fields] AND "agents"[All Fields]) OR "contraceptive agents"[All Fields] OR 
"contraceptives"[All Fields])).   
Studies were considered eligible if they were non-experimental (i.e., observational) studies of the 
association between oral contraceptive use and fibroid risk. Twelve eligible studies12–20,26,48,49 were 
identified from 184 abstracts and are described in Table 3.2.  
Overall, the literature on oral contraceptive use and fibroid status suffers from great heterogeneity 
in populations, methods, and comparisons, as well as several limitations described in Table 3.3.56 The 
most prevalent limitations were lack of baseline fibroid screening, and lack of outcome screening for all 
participants.12 Five studies12,13,19,20,26 relied on self-report for fibroid status. Sensitivity of fibroid self-report 
is low, and is highest (41%) in black women aged 35-45 years.57 Most studies (n=8)13,16,18–20,26,48,49did not 
describe which types of oral contraceptives were used by participants (e.g., combined or progesterone-
only). All studies took place after progestin-only oral contraceptives were introduced (as early as 1973).58 
Given that more recent literature suggests a protective association for progestin-only methods in African 
American women,12,50 perhaps conflicting results are due, in part, to differences in the proportion of 
women using estrogen-containing pills in each study, or differences in the distribution of formulations 
taken between studies.  
Table 3.4 describes the distribution of available comparisons in the literature. The most common 
assessment was for oral contraceptive exposure by duration of use (n=9), followed by time since last use 




Table 3.2. Characteristics of twelve observational studies of oral contraceptive use and fibroid risk 
Study 
(Country, period) 
Exposure Outcome  Comparator Design Analysis Effect 
Measure 
Key Findings 
1: Histologic detection of uterine leiomyoma  




Never users Case-control Logistic regression OR Current use protective (OR 
0.3, 95% CI: 0.2, 0.6) 
Lumbiganon, 1995 
(Thailand, 1991-3) 
COC † Fibroids,  
Histologic 
Never users Case-control Logistic regression OR Ever use protective (OR 
0.76, 95% CI: 0.66, 0.92) 




Never users Case-control Logistic regression RR No association 




Never users Case-control Logistic regression OR No association 






Case-control Logistic regression OR -> RR OCs protective. OR -> RR = 
0.54 to 0.90 (varies by time 
since last use and duration 
of use) 
2: Ultrasound detection of uterine leiomyoma 
Marino, 2004  
(Italy, 1996-8) 
COC † >= 1 yr. Fibroids, 
Ultrasound 
COC † < 1 yr. Cross-sectional Fisher's exact test None Shorter duration of use 
associated with UF (p < 
0.01) 
Faerstein, 2001  
(USA, 1990-93) 
COC † Fibroids, 
Ultrasound or 
histologic 
Never use Case-control Logistic regression OR Current use protective (OR 
= 0.2, 95% CI: 0.1, 0.6) 
3: Self-reported uterine leiomyoma 
Martin, 2011 
(USA, 2003-04) 
COC † Fibroids,  
Self-reported 
Non-users Cross-sectional Unadjusted  OR Current users vs. non-users: 
0.36 (0.12-1.04) 




Never users Prospective* Age- and time- stratified 
Cox regression 
IRR Early age of first OC use 
increased risk (IRR = 1.2) 
Chen, 2001  
(USA, 1978-87) 







Case-control Logistic regression OR No association (OR not 
reported) 
Marshall, 1998  
(USA, 1989-93) 
COC † Fibroids, Self-
reported 
Never users Prospective* Logistic regression RR OCs harmful when first used 
at ages 13-16 years: RR= 
1.39 (95% CI: 1.17–1.66) 
Samadi, 1996  
(USA, 1980-82) 




COC † < 3 mo. Case-control Logistic regression OR No association. OR = 1.0 
(0.7-1.6) (overall) to 5.0 
(infrequent pap smears 
group, significant) 
*While the parent study was prospective, the contraception/fibroid relationship examined was usually cross-sectional or retrospective in nature. No baseline screening was performed.  
 
†Oral contraceptives not otherwise specified, i.e., the study exposure was oral contraceptives but the authors did not describe what types were used (e.g., progestin-only or combined). 
Since combined formulations are more commonly used, we assume that the exposure under study was combined oral contraceptives.  
 
Abbreviations: BWHS=Black Women’s Health Study; CI=Confidence Interval; COC=combined oral contraceptive; HC=hormonal contraceptive; DMPA= depot medroxyprogesterone 
acetate ; IRR=Incidence Rate Ratio; IUD=intrauterine device; mo.=month(s); NHS=Nurse’s Health Study; OC=oral contraceptive; OR=Odds Ratio; PRR=Prevalence Risk Ratio; 






Table 3.3. Key limitations of twelve observational studies of oral contraceptive use and fibroid risk 











Chen (2001) x  x  xc 22% 
Chiaffarino (1999) x x  x  Not reported 
Faerstein (2001) x x x   10% to 40%b 
Lumbiganon (1995) x x x x  < 1% 
Marino (2004) x  x  xa Not reported 
Marshall (1998) x x x   Not reported 
Martin (2011) x x x   22% 
Parazzini (1988) x x xd x  Not reported 
Parazzini (1992) x x  x  Not reported 
Ross (1986) x x  x xe 0% 
Samadi (1996) x x x   9% 
Wise (2004) x x    100% 
Abbreviations: OC NOS=oral contraceptives not otherwise specified, i.e., the study exposure was oral contraceptives but the authors did not describe what types were used (e.g., 
progestin-only or combined). 
 
aAll women resided near Seveso, Italy in 1976 at the time of a chemical plant explosion which released high levels of dioxin. The study is intended to examine the reproductive 
health outcomes of these women. Current users were excluded, study includes former users only.  
 
b10% of controls, 40% of cases 
 
cConditioned on tubal sterilization. Mostly white, married, educated. 
 
dParazinni (1988) uses the same population as Parazinni (1992) which states that combined oral contraceptives were the type studied and that combined oral contraceptives 
represent most of the oral contraceptive use in Italy. 
 








Table 3.4. Comparisons reported in twelve observational studies of oral contraceptive use and 
fibroid risk 
Comparison Studies (n) References 
Duration of use 9 Chiaffarino; Faerstein; Marino; Marshall; Parazzini; Parazzini; Ross; Samadi; Wise 
Time since last use 7 Faerstein; Marino; Marshall; Parazzini; Parazzini; Ross; Wise 
Ever vs. Never 4 Chiaffarino; Lumbiganon; Parazzini; Parazzini 
Current vs. Never 4 Chiaffarino; Faerstein; Marshall; Wise 
Past vs. Never 4 Chiaffarino; Faerstein; Marshall; Wise 
Age at first use 4 Faerstein; Marshall; Martin; Wise 
Formulation 3 Chiaffarino; Ross; Wise 
Current vs. Non-user 2 Chen; Martin 
Time since first use 2 Chiaffarino; Parazzini 
 
Duration of use: Duration of use was never categorized the same way between any two studies. 
Three studies reported a protective association for longer duration of use: Chiaffarino et al. (1999) divided 
duration of use into 4 categories: 1 or fewer years, 2-3 years, 4-6 years, 7 or more years. Fibroid risk 
decreased with increasing duration of use (p-trend = 0.03) with ORs ranging from 1.4 (1 or fewer years) to 
0.5 (7 or more years). Ross et al. (1986) observed a linear trend for duration of use; fibroid risk was 
reduced by 17% for every 5 years of oral contraceptive use. Marino et al. (2004) reported that shorter 
duration of oral contraceptive use (< 1 year versus > 1 year) was associated with uterine fibroid 
prevalence (p < 0.01). The remaining six studies did not find any association between duration of use and 
fibroid status. 
Time since last use: Seven studies reported associations for time since last oral contraceptive 
use and fibroid status. No two studies used the same categorization scheme for time since last use. 
Marino et al. (2004) reported that longer time since last oral contraceptive use (> 5 year versus < 5 years) 
was associated with uterine fibroid prevalence (p < 0.01). The remaining six studies observed no 
association. 
Ever vs. Never use: Four studies reported odds ratios comparing ever to never oral contraceptive 
users. Lumbiganon et al. (1995) reported a protective association of OR = 0.76 (95% CI: 0.66-0.92). 
Three studies reported null findings: Chiaffarino et al. (1999) OR = 1.1 (95% CI: 0.8-1.3); Parazzini et al. 
(1988) OR = 1.4 (95% CI: 0.9-2.1); Parazzini et al. (1992) OR = 1.1 (95% CI: 0.8-1.5).  
Current vs. Never use: Two studies reported a protective association between current use of oral 
contraceptives and fibroid status, when comparing current to never users: Chiaffarino et al. (1999) [OR = 
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0.3, 95% CI: 0.2-0.6], and Faerstein et al. (2001) [OR = 0.2, 95% CI: 0.1-0.6]. The remaining two studies 
reported no association.   
Past use vs. Never use: Marshall et al. (1998) found a potentially harmful association (RR = 1.31, 
95% CI: 1.03-1.66) between past oral contraceptive use and fibroid incidence when comparing former to 
never users. The remaining three studies found no association. 
Age at first use: Two studies reported a potentially harmful effect of early onset oral contraceptive 
use. Marshall et al. (1998) divided age at first use into four categories: 13-16 years, 17-20, 21-24, 25 
years or older. Women who started oral contraception between ages 13 and 16 years were 1.26 times as 
likely to develop uterine fibroids when compared to never users (RR = 1.26, 95% CI: 1.05-1.51). The RR 
was higher when counting only hysterectomy confirmed cases (RR  = 1.90, 95% CI: 1.29-2.79). Overall, 
earlier age at first use was associated with positive fibroid status (p-trend 0.003) when only hysterectomy 
confirmed cases were counted. Wise et al. (2004) divided age at first use into four categories: < 17 years, 
17-20 years, 21-24 years, 25 years or older. Initiating oral contraceptive use prior to age 20 was 
associated with fibroid incidence when compared to never-use: IRR = 1.2 for both the < 17 and 17-20 
years groups, 95% CIs: 1.0-1.4 and 1.0-1.3, respectively. Earlier onset of oral contraceptive use was 
associated with fibroid status (p-trend 0.005). The remaining two studies reported no association: Martin 
et al. (2011) found no association when comparing oral contraceptive initiation before and after age 17. 
Faerstein et al. (2001) found no association between age at first oral contraceptive use and fibroid status 
(OR and age categories not reported).  
Formulation: To account for differences in oral contraceptive formulation over time, Chiaffarino et 
al. (1999) stratified their results by time period (high and lower estrogen eras). For oral contraceptive use 
prior to 1991, a null but potentially protective association was found between current versus never use of 
oral contraceptives and fibroid status (OR = 0.4, 95% CI: 0.1-1.8). For oral contraceptive use 1992 and 
later, a protective association was found (OR = 0.3, 95% CI: 0.2-0.7). Ross et al. (1986) reported that 
higher doses of progesterone in combined oral contraceptive pills yielded greater protection against 
fibroids. However, formulations containing ethynodiol diacetate (a form of progesterone) were not 
protective. Interestingly, Wise et al. (2004) later found that hormonal contraceptives containing ethynodiol 
diacetate may yield a harmful effect on fibroid risk (IRR = 1.6, 95% CI: 1.1-2.5, never use of any oral 
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contraceptive as comparator). Wise et al. (2004) found no relationship between fibroid risk and estrogenic 
potency, progestational potency, progestin classification, monophasic, biphasic or triphasic estrogen 
formulations.  
Current vs. non-user: Martin et al. (2011) compared current users to non-users and found a 
protective association (OR = 0.36, 95% CI: 0.12, 1.04). Chen et al. (2001) found no association.  
Time since first use: Two studies reported a null association between time since first oral contraceptive 
use and fibroid status. Chiaffarino et al. (1999) divided time since first use into four categories: 5 or fewer 
years, 6-10 years, 11-15 years, 15 or more years, comparing each category to Never use. The OR for the 
“5 or fewer years” group was 0.6 (95% CI: 0.4-1.1). The remaining ORs were also null (1, 1.1, and 1). 
Parazzini et al. (1992) also reported no association between time since first oral contraceptive use and 
fibroid status, comparing time since first use less than 15 years, and time since first use 15 years or 
longer to never-use.  
Black Women’s Health Study (BWHS): The most similar study to the one proposed was published 
in 2004. Lauren Wise et al. (2004)12 assessed the association between self-reported hormonal 
contraceptive use and self-reported uterine fibroids identified by ultrasound or hysterectomy (of which a 
subsample were validated) in 22,895 premenopausal black women with no prior diagnosis of fibroids who 
participated in the Black Women’s Health Study (BWHS) in 1997-2001. Associations were explored using 
age- and time-stratified Cox regression models. The average follow-up time was 40 months (76,711 
person-years/22,895 women = 3.35 x 12 = 40.2) and 10% of participants reported fibroids by the end of 
the study period (2,279 new cases in 22,895 women). In contrast, the SELF cohort (also 100% black 
women) reported the same incidence in half the follow-up time. SELF does not require women to seek 
medical treatment in order to be screened for fibroids, as fibroid screening is performed for all women. 
Furthermore, the BWHS included an older cohort than SELF (BWHS median age = 34 years [IQR 29-40], 
SELF median age = 29 years [range 23-35]). Given that fibroids tend to occur in older women, we would 
expect an older cohort to have more fibroids, not fewer.6,28 Our prospective design with baseline and 
follow-up screening in all participants represents a substantial step forward. 
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CHAPTER 4: RESEARCH PLAN AND METHODS 
Study Design 
This cross-sectional (Aims 1-2) and prospective (Aims 2) cohort study investigated whether oral 
contraceptive use (including age at first use, duration of and time since last use) is associated with 
incidence and prevalence of uterine fibroids. To do this, we leveraged existing prospective data from the 
Study of Environment, Lifestyle & Fibroids (SELF), based on the follow-up of 1,696 young (23-34 
years), black women living in the Detroit, Michigan area in 2010-2016.  
Using SELF as a parent study for these aims allowed us to capitalize on a rich, existing database 
created specifically to examine fibroid development. SELF data are uniquely poised to discover factors 
operating early in the development of fibroid tumors.27 This is because SELF conducts routine 
ultrasounds on black women in the relevant age-range for initial fibroid disease, and is therefore able to 
capture new fibroids soon after they form (and prior to the onset of symptoms). The SELF cohort was also 
created specifically to monitor growth of existing fibroids.2,25 There is no comparable existing database, to 
our knowledge, and no more efficient way to study the risk factors for this disease.  
Study Population 
SELF focuses on black women since this ethnic group experiences greater risk and earlier onset 
of fibroids.2 SELF enrolled 1,696 African American women aged 23-34, meeting the study 
inclusion/exclusion criteria described below. Our study did not impose any additional eligibility criteria. 
Inclusion/Exclusion Criteria: 
• Ages 23-34 years 
• Self-identify as Black, African American, or part-African American 
• No prior clinical diagnosis of uterine fibroids 
• Intact uterus (no prior hysterectomy) 
• Not currently pregnant (may enter study 3 months after pregnancy) 
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• Residence in the United States 
• Able to attend clinic visits in Detroit, MI 
• Committed to remain in study for five years 
• No prior diagnosis of cancer that required radiation or chemotherapy 
• No prior diagnosis of lupus, Grave's disease, Sjogren's scleroderma, or multiple sclerosis that 
required medication 
 
Women were recruited from the entire Detroit area via local radio and television commercials, 
advertisements in newspapers and magazines, brochures at healthcare clinics, and information booths at 
community events. In addition, African American women aged 23-34 seen at the Henry Ford Health 
System (HFHS) were sent letters describing SELF and inviting them to participate.2  
Participants received $150-200 for enrollment activities, $100-120 for follow-up activities every 15 
months (4 follow-ups), and $100 bonus for completing all study activities. Enrollment required a telephone 
eligibility screening, a 30-60 minute orientation done in-person or over the phone, a self-administered pre-
enrollment questionnaire, informed consent, a clinic visit, and three questionnaires before or during the 
clinic visit.  
Retention rate was high at 87% for the 20-month follow-up.2 The 20-month follow-up produced 
useable ultrasounds for 1,421 participants. To ensure high retention at 40-months’ follow-up, three 
mailings per year were sent to study participants: two newsletters and a holiday card. Data collection for 
the 40-month follow-up is currently ongoing.  
Similar to the Black Women’s Health Study, SELF participants are more educated than U.S. black 
women overall (78% versus 60% with more than a high school education at 25-34 years of age)2 We 
believe this to be a result of enrolling only women who could committ to participating for the full 5-year 
study period.2 
In recognition of the potential for recruitment bias, women were asked about their three main 
reasons for enrolling in the study. Options included: family history, a friend or relative told me I should 
participate, I worry that I might have fibroids, desire to contribute to knowledge about African-American 
women’s health issues, to get general health information, and other (please specify).  
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Preliminary Data 
Previous studies confirm the suitability of SELF data for the study of fibroid growth and related 
risk factors. The SELF data have been used in multiple, published studies of uterine fibroid 
development.25,50,59,60 Most relevant is a cross-sectional study of the association between depot 
medroxyprogesterone acetate (DMPA; a progestin-only, injectable hormonal contraceptive) duration of 
and time since last use and uterine fibroid prevalence. A strong protective association was found between 
ever use of DMPA and the presence of uterine fibroids. Longer duration of DMPA use (i.e., greater 
cumulative lifetime exposure) was associated with a lower prevalence of uterine fibroids. This protective 
association was seen even among women who had not used DMPA for several years.50 This published 
study confirms the suitability of the SELF data for the investigation of duration and time since last use of a 
specific contraceptive type in relation to uterine fibroids. Our study combined this exposure data with 
prospective data on incident fibroids and prevalent fibroids, with a focus on oral contraceptives. An 
analogous, prospective study of DMPA use and fibroid incidence is currently being carried out by 
members of our team at NIEHS, specifically, Quaker Harmon, PhD and Donna Baird, PhD.  
Exposure Assessment and Quality Assurance 
HC Utilization 
History of hormonal contraceptive use for SELF was collected via telephone interview as part of 
the enrollment questionnaire. Participants were asked if they had ever used each of the following types of 
contraception: birth control pills, a hormonal implant, a hormonal patch, a hormonal vaginal ring, a 
hormonal shot, an intrauterine device (IUD), and emergency contraception. Brief descriptions and 
examples of common brand names were provided for hormonal implants, shots, and emergency 
contraception.  
For each type of contraceptive, excluding emergency contraception, women were asked about 
their (i) age at first use, (ii) whether or not they were currently still using, (iii) how old they were when they 
stopped using, and (iv) their reasons for using. In addition, women who had used oral contraceptives 
were asked whether or not they had ever stopped using for a month or longer, and if so, their reasons for 
stopping, and the proportion of time that they spent on oral contraception.  
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Ever use of combined oral contraceptives (COCs) 
COC users were identified based on their responses to items in the Contraceptive History 
questionnaire, as read by a telephone interviewer. Women were first asked, “Have you ever used birth 
control pills,” and were later asked, “Have you ever used a progesterone-only  birth control pill, or 
“mini-pill”, such as Micronor, Nora-BE, or Ovrette?” If women answered affirmatively to both 
questions, we used further data to determine whether or not they had used COCs, the mini-pill, or both. In 
order to do this, we assessed age at first use data (i.e., “How old were you when you started using 
birth control pills, whether or not it was to prevent pregnancy?” and “How old were you when you 
started taking a progesterone (pro-JES-ter-own)-only pill or “mini-pill” (such as Micronor (MY-cro-
nor), Nora-BE (NOR-ah-BEE), or Ovrette (oh-VRETT))?”), and data regarding timing of discontinuation. 
For the non-specific “pill” questions, women were asked whether or not they were still currently using the 
pill and if not, how old they were when they stopped. For the mini-pill women were not asked how old they 
were when the stopped using, but were instead asked how many years and months in total that they used 
the mini-pill. If age at first mini-pill use was equal to age at first pill use, and age at last pill use minus age 
at first pill use was the same as the years of mini-pill use, then women were considered to have used the 
mini-pill only. If age at first mini-pill use was equal to age at first pill use, and age at last pill use minus age 
at first pill use plus one additional year was the same as the years of mini-pill use, then these women too 
were considered to have used only the mini-pill and not combined oral contraceptives. Additionally, for 
current pill users, if start age for pill and mini-pill were the same, and current age minus pill start age was 
the same as years of mini-pill use, then these women too were considered to have used only the mini-pill. 
Data were quality checked by examination of individual records as well as re-coding in SAS using 
different logic to achieve the same results for verification. Additional code was written to take months of 
mini-pill use into consideration, as a quality assurance investigation.  
Women who were not found to have used the mini-pill only based on these rules were considered 
to have used combined oral contraceptives in addition to or instead of the mini-pill. Women who 
answered “Unsure” to “Have you ever used a progesterone-only  birth control pill, or “mini-pill”, 
such as Micronor, Nora-BE, or Ovrette?” were considered to have used combined oral contraceptives 
only (n=48). Records for these 48 women were hand checked for signs of incorrect classification. 
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HC Sequences of Use 
For HC sequencing for our Aim 1 analyses, each participant’s list of HC types was sorted by age 
at first use. When two or more HCs of different types were initiated at the same age, additional steps 
were taken to determine which HC was used first. Note that while the data provided for each hormonal 
intrauterine device (H-IUD) to be listed separately, the age at first use for any H-IUD was used, and 
repeat use of the same HC type was not included in our final sequencing. Furthermore, due to data 
sparsity and interpretability of the resulting figures, use of emergency contraceptives was ultimately not 
included in our HC sequence analyses.  
There were n=148 women with one or more age at first use ties. Of these, n=13 were determined 
to have used progestin-only pills only, and thus their data for COCs and mini-pill were merged and re-
labeled “mini-pill.” An additional n=39 women were found to have the same start and stop age for one HC 
type and not the other (e.g., used patch at ages 17-17 years and mini-pill at ages 17-19 years). For these 
cases, the HC type with the same start and stop age was considered to have come first. Data for n=9 
users was resolved using additional available data regarding HC use and pregnancy timing. The HC type 
reportedly used within 12-14 months of a pregnancy that occurred one year prior to the tied age was 
considered to have come first. For n=7 women, mini-pill stop age was less than the stop age reported for 
“the pill.” Since age at first use of “the pill” was not specific to combined or progestin-only types, when age 
at first use of “the pill” was the same as age at first use of the mini-pill, and mini-pill stop age was less 
than “pill” stop age, we considered mini-pill use to have come first. One additional tie was resolved after 
examining the data and discovering a subject with duplicate intrauterine device data (i.e., the same 
device was reported twice). By these same rules, n=29 individuals were found to have data that was 
already in the proper order for sequence of use. Thus, of 148 women with age at first use ties, data were 
corrected for 68, while 29 were already in the correct order, and 50 remained unresolved. The 50 
unresolved records were not included in analyses regarding sequences of use. Of these unresolved ties, 




Duration of Use of COCs 
Cumulative lifetime exposure to (duration of use of) combined oral contraceptives (COCs) was 
calculated by subtracting age at first OC use from age at last OC use (or current age, if the woman is a 
current user). For women who stopped using OCs for a month or longer, we multiplied the resulting 
difference in years by the proportion of time they spent using OCs. For women who reported a history of 
mini-pill use, we subtracted the total amount of time that they were using the mini-pill from the total 
amount of time that they had spent using OCs. For quality assurance, we tested two different orders of 
operation, one in which weighting preceded subtraction of mini-pill duration, and another in which 
subtraction of mini-pill duration preceded weighting. We then examined the resulting distributions for 
plausibility (e.g., negative durations of use), and compared individual durations of use to length of time 
using OCs for heavy menstrual bleeding among the subset of women who used OCs for relief from 
perceived menorrhagia. We found that the weighted last approach (i.e., subtracting mini-pill duration of 
use from OC duration of use prior to applying weights for proportion of time spent using OCs) yielded 
more plausible and reliable estimates. Women who reported the same stop and start age for OCs and 
had not used the mini-pill were assigned a value of 6 months for duration of COC use. 
Duration of use could not be calculated using the above methods for n=2 women due to missing 
data. For our Aim 2 analyses, we hard-coded age at first pill use for one woman with missing data for that 
variable, based on determinations made during a careful record review of her individual data. This 
determination was made using additional HC data that was available for the time period surrounding a 
particular pregnancy. Duration of use was hard-coded for an additional woman for whom information on 
pill discontinuation was missing. Adjudication for this case was also based upon pregnancy history. 
Time since Last Use of COCs 
Time since last combined oral contraceptive use was calculated by subtracting the age at last pill 
use from current age at baseline. Current pill users who were not mini-pill users were assigned a time 
since last use value of zero. Of n=64 women who had used both COCs and the mini-pill, time since last 
COC use could not be determined for n=33. Case-by-case adjudication and subsequent application of 
logic (i.e., SAS code) allowed for determination of the remaining n=31. It was determined that if times 
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since last use as calculated for OCs and mini-pill worked out to be at least 3 years apart, we could be 
relatively sure that the time since last "pill" use was referring to COCs and not the mini-pill (n=31). 
Reliability of Self-Reported COC Data 
Self-reported history of oral contraceptive use, as collected by telephone interview, has been 
found to be reliable compared to automated pharmacy dispensing data.61 A study of women aged 45-59 
years found almost perfect (95%) agreement for use in the last 5 years, and substantial agreement (85%) 
for use in the last 15 to 20 years.61 SELF participants were much younger (23-34 years of age at 
enrollment) and should have comparable, if not better, recall of their oral contraceptive history. 
Outcome Assessment and Quality Assurance 
Fibroid identification was performed with the iU22 ultrasound system (Philips Healthcare, Bothell, 
WA) or a LOGIQ9 system (GE Healthcare, Milwaukee, WI) of a similar age.2,25 A standardized data 
collection form was used by all sonographers, with a diagram of the uterus so that fibroids could be 
mapped for future reference. Fibroids were carefully mapped, measured, and numbered.2 Sonsographer, 
machine, and probe IDs were recorded for most exams.  
SELF sonographers are registered diagnostic sonographers with at least 3 years of experience in 
gynecologic sonography. All sonographers were given additional, study specific training, and training to 
distinguish fibroids from other uterine pathologies.2  
Quality control procedures were carried out. The head sonographer reviewed 8% of each 
sonographer’s examinations each month. It is estimated that 98.5% of women considered fibroid free at 
baseline were truly fibroid free, and 99.6% of women with fibroids at baseline truly had fibroids.2 
At each SELF study visit (i.e., baseline and follow-up visits), each individual fibroid was measured 
3 times in 3 perpendicular planes, resulting in 9 diameter measurements for each fibroid.25 Fibroid 
diameters were measured in centimeters (cm). When transvaginal ultrasound (TVUS) was infeasible 
(e.g., patient discomfort), transabdominal ultrasound was used instead. This was quite rare (~2%), 
however.25 
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To examine the associations between oral contraceptive use and risk or prevelance of uterine 
fibroids (Aim 2), women were counted as having uterine fibroids if they had one or more lesions of 0.5 cm 
maximum diameter or larger that could be visualized in all three planes.25  
Transvaginal ultrasound (TVUS) is the current standard of care for uterine fibroid assessment.62 
TVUS has 99% sensitivity and 91% specificity for detecting uterine fibroids.63 Furthermore, TVUS has 
high and equal accuracy to magnetic resonance imaging (MRI) at measuring fibroid diameter.63 
Covariates 
Covariate Assessment 
The following covariate data were collected by telephone interview near the time of enrollment: 
current age, age at menarche, family history of uterine fibroids, smoking status (never, past, current), 
alcohol intake, parity, breastfeeding history, reason(s) for hormonal contraceptive use (including oral 
contraceptive use), history of using other types of hormonal contraceptives, and history of sexually 
transmitted diseases (gonorrhea, chlamydia, trichomonas, syphilis, bacterial vaginosis, mycoplasma 
genitalium, genital warts, human papillomavirus, and herpes). Body mass index (BMI) was calculated 
from height and weight as measured at the baseline clinic visit. Each of these covariates could be related 
to uterine fibroid development, as previously documented in the literature.6  
Covariate Selection 
For Aim 2 analyses, two sets of covariates were utilized: one for inverse probability of treatment 
and standardized mortality ratio weighting and the other for inverse probability of censoring weighting. 
Covariates were selected after a several-months’ long process of discussion with committee members, 
including senior fibroid epidemiologists (DB, QH), a practicing OB/GYN clinician-researcher (WKN), 
pharmacoepidemiologists (MJF), general epidemiologic methodologists (CP), a biostatistician (MH), and 
the dissertation chair (JSS). Discussion of covariate selection drew from a combination of directed acyclic 
graphs (DAGs), existing literature, clinical knowledge, and knowledge from decades of combined prior 
experience studying fibroids or hormonal contraceptive use. These discussions along with the available 
data informed covariate selection as well as the cut points chosen for those covariates. 
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Covariate Sets for Weight Calculations 
The covariate set for calculating inverse probability of treatment and standardized mortality ratio 
weights included age in years (continuous), age at menarche (<11 years), Depo-Provera duration of and 
time since last use (never use, short/past, long/past, short/recent, long/recent), total implant and H-IUD 
duration of use (>24 months), time since last birth (<5 years, 5-9.99 years, >10 years and no birth), parity 
(nulliparous, 1-2 births, >3 births), BMI (>30, remaining values according to tertile), and education 
(Bachelor’s degree or higher). 
The covariate set for calculating inverse probability of censoring weights included the exposure 
relevant to the present model, the covariate set for the inverse probability of treatment weights as 
described above, as well as annual household income (<$20,000, $20,000-49,999, and >$50,000 ), 
baseline employment status (not employed, employed <30 hours per week, employed >30 hours per 
week), smoking history (never smoked, former smoker, current smoker of <10 years, current smoker of 
>10 years) and history of heavy “gushing” type menstrual bleeding (yes/no). 
Because parity and Depo-Provera use have been shown to be highly protective against uterine 
fibroids45,48,50 and would likely be associated with COC use and levels of COC use, sensitivity analyses 
were carried out that took into account parity and Depo-Provera use during follow-up. For these analyses, 
parity during follow-up was dichotomized (yes/no), and Depo-Provera use during follow-up was 
dichotomized as 9 months or less and greater than 9 months of use during follow-up. 
Body Mass Index (BMI) Tertiles for Aim 2 Analyses 
 It was agreed upon by the main author (SRH) and committee members with expertise in fibroid 
epidemiology (QH, DB) that body mass index (BMI) would be divided into four categories: BMI >30 
(obese) with the remaining values divided into thirds. Since our ever/never COC comparisons were 
among the entire cohort while the within COC users comparisons were among COC users only, tertiles 
for BMI <30 differed for these two analytic cohorts. BMI tertile cut points for the ever/never (full) cohort 
were 23.5468 and 26.7127. BMI tertile cut points for the COC users for the remaining analyses were 
23.7395 and 26.8021.    
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Data Analysis Plan 
Aim 1. Describe the patterns of and reasons for hormonal contraceptive use prior to and at 
enrollment among women enrolled in SELF, including the duration of and time since last use of 
oral contraceptives.  
For Aim 1, we constructed hormonal contraceptive biographies24 for each study participant. A 
woman’s contraceptive biography consisted of a timeline of her hormonal contraceptive use, including the 
types of hormones and routes of administration used, in order of initiation. We also examined participants’ 
primary reasons for using each type of hormonal contraceptive (e.g., to prevent pregnancy, control 
menstrual bleeding, treat acne).  
We described the distribution of HC utilization by HC type for HCs ever used and currently in use 
at enrollment. We also report number of HC types ever used, first HC type used, age of first HC use and 
total duration of HC use in years. For each HC type (e.g., COC, patch, ring, shot, H-IUD, mini-pill, and 
implant) we report age at first use, years since menarche of first use, total months used, and reasons for 
using (e.g., birth control, menstrual problems). Annual initiation rates were plotted, and compared to 
regulatory approval timelines. We constructed Sankey diagrams to depict HC sequences of use, and 
plotted cumulative incidence curves for menarche and HC initiation. Knowledge of these patterns 
provided meaningful context to the findings from the following aim.  
These descriptive findings characterized hormonal contraceptive use sequences and 
characteristics among a cohort of black women living in the Detroit, Michigan area in 2010-2016. 
Knowledge of these patterns gave meaningful context to findings for the subsequent study aim.  
Aim 2. Examine the associations between different levels of combined oral contraceptive 
(COC) use and the 40-month cumulative risk of uterine fibroids, and baseline fibroid prevalence.  
To examine the association between combined oral contraceptive (COC) use and 40-month 
cumulative risk of uterine fibroids, as well as fibroid prevalence at baseline, women were counted as 
having uterine fibroids if they had one or more lesions of 0.5 cm maximum diameter or larger that could 
be visualized in all three planes.25 Cumulative lifetime exposure (duration of use) and time since last use 
of COCs were treated as ordinal variables, i.e., <1 year, 1-1.99 years, 2-4.99 years, and >5 years for 
duration of use, and 0 [current], 1-2 years, 3-4 years, and >5 years for time since last use. Joint duration 
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of and time since last COC use was also examined. For this variable, duration of use was characterized 
as short (< 2 years) or long (> 2 years), and time since last use was characterized as recent (< 5 years) or 
past (> 5 years). Selection of all cut points was informed by a variety of factors including prior literature, 
clinical utility, and ability to achieve covariate balance in the propensity score analyses (i.e., strata sample 
size).  
Ever use and age at first use of COCs were analyzed as dichotomous variables in the entire 
cohort. The following comparisons were restricted to ever COC users. Age at first use was dichotomized 
as less than 17 years and 17 years or older, based on findings from prior literature.12,13,26 The lowest age 
at first use category (i.e., <17 years) served as the referent. Cumulative lifetime exposure (duration of 
use) and time since last use were analyzed as ordinal variables, to allow for comparison to findings of 
previous studies. The lowest amount of cumulative lifetime exposure and the shortest time since last use 
(i.e., current users) served as referents.  
First, we examined the association between ever COC use and prevalent fibroids at baseline. 
This cross-sectional analysis included all women enrolled in SELF. Subsequently, we examined the 
associations between prevalent fibroids and each of four exposures: age at first COC use, duration of 
COC use, time since last COC use, and joint duration of and time since last COC use. These analyses 
were restricted to COC users, comparing each category of use to the lowest level. Second, we carried out 
incidence analyses analogous to the prevalence analyses just described. This allowed us to examine the 
associations between incident fibroids and different levels of COC use. To establish temporality, women 
were included in our incidence analyses if their baseline ultrasound showed no fibroids. Further details 
regarding follow-up and censoring are presented in Chapter 6. 
All analyses for Aim 2 were performed in SAS 9.3 or higher. We report our propensity score (PS) 
based methods in greater detail in Chapter 6. In brief, inverse probability (IP) weights were constructed 
for all exposures, and censoring. Standardized mortality ratio (SMR) weights were constructed for ever 
COC use. For incidence analyses, the IP and SMR weights were multiplied by the inverse probability of 
censoring weights. Weighted risk and prevalence ratios were calculated comparing each level of COC to 
the lowest level of use, and comparing ever to never COC use. Pregnancy and hormonal contraceptive 
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use during follow-up were taken into account in sensitivity analyses (see Chapter 6 for further description 
of sensitivity analyses). 
Study Power 
With data from the SELF cohort, we were well powered to rule out strong protective or harmful 
associations. A priori power analyses were carried out using PROC POWER in SAS 9.4 to determine 
which magnitude associations could be “ruled out” by our data. 
Initially we had planned to perform survival analysis and to calculate risk differences. For Aim 2, 
comparing ever oral contraceptive users to never users, we determined that we had >80% power to 
detect a protective risk difference of -0.068 percentage-points and lower. Furthermore, we had >80% 
power to detect a harmful risk difference of 0.080 and higher. For the Cox proportional hazards model, 
treating competing risks as censored events, and comparing ever to never oral contraceptive users, we 
determined that we would have >80% power to detect a protective hazard ratio of 0.645 and lower. Thus 
we determined that we had excellent power to detect associations of clinical and public health relevance.  
Our a priori calculations assumed that 20% of women in the never-users group would develop 
fibroids by 40-months’ follow-up. This was a reasonable assumption given the 10% incidence observed 
for the 20-month follow-up, and based on the fact that SELF consists of a race and age groups known for 
elevated fibroid incidence. These calculations were restricted to women without fibroids at baseline for 
whom 20-month follow-up ultrasounds were available (n=1,119).  
Using the exposure and outcome distributions of the final analytic cohort, further power analyses 
were conducted. In actuality, 17% of women who were fibroid-free at baseline (n=1,308) developed 
uterine fibroids by 40-months’ follow-up. We went further to calculate power for COC levels of use 
comparisons and for risk ratios rather than hazard ratios as originally planned for. 
For our Aim 2 prevalence analysis, comparing ever combined oral contraceptive users to never 
users, we had >80% power to detect a protective risk ratio of 0.739 and lower. Furthermore, we had 
>80% power to detect a harmful risk ratio of 1.295 and higher. For our smallest number comparisons 
(time since last use 1-2 years ago versus current users), we had >80% power to detect a protective risk 
ratio of 0.538 and lower and a harmful risk ratio of 1.545 and higher.  
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For our Aim 2 incidence analysis, comparing ever combined oral contraceptive users to never 
users (among those not censored), we had >80% power to detect a protective risk ratio of 0.689 and 
lower. Furthermore, we had >80% power to detect a harmful risk ratio of 1.356 and higher. For our 
smallest number comparisons among those not censored (time since last use 3-4 years ago versus 
current users), we had >80% power to detect a protective risk ratio of 0.345 and lower and a harmful risk 
ratio of 1.835 and higher.  
Thus we had excellent power to detect associations of high clinical and public health relevance. 
We were extremely well powered to rule out two-fold harmful associations, with power ranging 
from 0.913 to >0.999 for risk ratios of 2.00 in our main analyses. We could universally rule out 
associations of 0.345 magnitude and lower in all of our analyses, and 0.50 and lower in most of our 
analyses. Thus, our study is of tremendous value to both patients and prescribers.  
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CHAPTER 5: PATTERNS OF AND REASONS FOR HORMONAL CONTRACEPTIVE USE IN THE 
SELF COHORT (PAPER 1) 
Introduction 
The use of hormonal contraceptives (HCs) in the U.S. has increased since the 1990s and 
continues to rise.10,41 At least 80% of American women are ever users of HCs, 9,64 and approximately 20% 
of U.S. reproductive-age women are current HC users.10 
In the 1990s and early 2000s, the U.S. saw a dramatic increase in the number of available HCs, 
from the initial approvals of implantable and injectable contraceptives (referred to as long-acting 
reversible contraceptives, or LARC) to the introduction of the patch and the ring.9,65 Prior to these 
advances, options for HC use were largely limited to oral contraceptive pills. Newer, longer acting HC 
options promised greater convenience for users, theoretically translating to improved uptake and correct 
and consistent use, thereby preventing more unwanted pregnancies – an issue of tremendous public 
health importance.66–68  
In this new context, contraceptive selection is related to convenience, cost, side effects, peer 
utilization, and awareness of method,69–72 and many women try more than one HC route in their 
lifetime.9,23 Yet, there are no published reports on women’s lifetime trajectories or sequence of HC use, 
cumulative lifetime exposure to HCs, or biological timing of use (i.e., initiation relative to menarche). 
Studies of reasons for HC use are relatively limited, and mainly concern reasons for choosing one HC 
type over another,69–72 as opposed to clinical indication(s) for use.  
We collected HC history in a cohort of women who came of age during the 20-year period in 
which the variety of available HCs increased dramatically in the U.S.9,65 Our objective was to describe 
their patterns of and reasons for HC use, as well as cumulative HC exposure, age at first use, initiation 






The Study of Environment, Lifestyle & Fibroids (SELF) is a prospective cohort study of 1,693 
young (23-35 years), African American women living in the Detroit, Michigan area. SELF was designed to 
investigate risk factors for uterine fibroid incidence and growth.2,21,22 Recruitment and baseline data 
collection were completed in 2010-2013.50 Participants were recruited from the Detroit area via local radio 
and television commercials, advertisements in newspapers and magazines, brochures at healthcare 
clinics, information booths at community events, and via the Henry Ford Health System (HFHS).2 The 
primary eligibility requirements were age, self-identified African American/black, and having no prior 
clinical diagnosis of uterine fibroids. SELF was approved by the institutional review boards of the National 
Institute of Environmental Health Sciences and the Henry Ford Health System.  
Data Collection on HC Use 
As part of participation in SELF, the lifetime history of HC use to date was collected via telephone 
interview as part of an enrollment questionnaire. Women were asked if they had ever used each of the 
following types of HC: “birth control pills” (oral contraceptives; OCs), “mini-pill” (progestin-only OCs), 
hormonal implant, hormonal patch, vaginal ring, “hormone shots like Depo-Provera,” and hormonal 
intrauterine devices (H-IUD). Brief descriptions and examples of common brand names were provided for 
hormonal implants and shots.   
For each HC type (and separately for each H-IUD), women were asked about their age at first 
use, whether or not they were currently using, how old they were when they stopped using, and their 
reason(s) for using. Women who had used OCs were asked whether or not they had ever stopped using 
for a month or longer, and if so, the proportion of time between start and stop that they spent on OCs 
(“very little of that time,” “less than half of that time,” “about half,” “more than half,” “most of that time,” “the 
entire time”). Women who used the “mini-pill,” implant, patch, ring, or shot were asked to state the total 
number of months and years that they had used each method prior to study enrollment. This study 
focuses primarily on the ever users of HC types described above. Emergency contraception (EC) is not 
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included as an HC method, but age of first use of EC was collected and is examined in some aspects of 
the analysis. 
Chronological Sequence of HC Use by Type 
Chronological sequences of HC use for each woman was constructed by sorting each woman’s 
HC types by age at first use. When a woman started more than one HC at the same age, records were 
adjudicated for correct order of use. Ties were resolved by examining discontinuation ages and 
pregnancy information. The relatively few records that could not be resolved were excluded from relevant 
analyses. EC was not included in the sequence analysis. 
Duration of Use for COCs and H-IUDs 
Duration of use estimates for combined oral contraceptives (COCs) were calculated in three 
steps: (1) Subtract age at first OC use from age at last OC use, or age at enrollment for current users, (2) 
Subtract months and years on the mini-pill, (3) Multiply by the proportion of time spent using OCs. 
Weights were applied as follows: 10% for “very little of that time,” 25% for “less than half of that time,” 
50% for “about half,” 75% for “more than half,” 90% for “most of that time,” and 100% for “the entire time.” 
When age at first use and age at last use were identical, a duration of six months was assigned. Duration 
of use for H-IUDs was calculated by subtracting age at first use from age at last use, or age at enrollment 
for current users, for each H-IUD. 
Reasons for HC Use 
Women were asked about each of the following reasons for using each HC type: “to prevent 
pregnancy;” “irregular menstrual cycles, or to regulate how often you had periods;” “heavy bleeding;” 
“menstrual pain;” or “any other reason.” Women who reported “any other reason” were asked to report the 
other reason(s).  
Data Management and Analysis 
All data management and analyses were performed in SAS 9.4 (SAS Institute, Cary, NC, USA). 
Sankey diagrams for sequences of HC use were created using a free online tool called SankeyMATIC 
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(http://sankeymatic.com/). Annual initiation rates for seven HC types were plotted using age at first use for 
each type (methods are further described in Figure 5.1 and Appendices 1.2 and 1.3). Cumulative 
incidence of menarche was plotted alongside cumulative incidence of HC initiation, using age at 
menarche and earliest age of use for any HC type (methods are further described in Appendix 1.1).   
Results 
Characteristics of SELF Cohort 
Age at enrollment ranged from 23 to 35 years, with a median age of 29 (IQR = 26, 32; Table 5.1). 
The majority (82%) of participants reported a gross annual household income of less than $50,000. Most 
(62%) were employed (data not shown). Many women who enrolled in SELF had completed a bachelor’s 
degree or higher (28%). A majority (80%) were overweight or obese. Twenty-six percent were current or 
former smokers (Table 5.1).    
Menarche was most frequently (64%) reported to have occurred during ages 11-13 years 
(Median [IQR] = 12 [11, 13]; Table 5.1). Mean and median time between menarche and enrollment were 
16.7 and 17.0 years respectively (range: 5-26 years; IQR 14-20 years).Thirty-seven percent reported a 
history of heavy menstrual bleeding, with a median age of onset of 19 years. Sexual debut was most 
often (61%) reported to occur during ages 14-17 years. Majority (61%) had given birth at least once. 
Median age for first pregnancy and birth were 19 and 20, respectively (data not shown).  
HC Utilization 
Ever use of HCs was common in this cohort (n=1,455; 86%). HC initiation took place in 1988-
2012. Self-reported HC initiation dates were well aligned with regulatory approval dates (Figure 5.1). 
Ever use of estrogen-containing HCs was reported by 87% of ever-HC users (Table 5.2). COCs 
were the most frequently reported HC type ever used (81%). Ever use of progestin-only HCs was 
reported by 59% of ever-HC users. Depo-Provera shot was the most commonly reported progestin-only 
HC type used, with ever-use reported by 49% of ever-HC users. More than half of ever-HC users (58%) 
had used both estrogen-containing and progestin-only HCs (Table 5.2). One in four (25%) reported use of 
EC (Table 5.1).  
39 
Twenty-eight percent of participants were using HCs at the time of study enrollment (Table 5.2). 
Of those women using HCs at the time of enrollment, half were using an estrogen-containing type, and 
half were using a progestin-only type (Table 5.2). The most frequently reported “current” HC types used 
were COCs (43%), H-IUDs (26%), and Depo-Provera (21%).  
HC Sequences of Use 
Among women who ever used HC, most (57%) reported using two or more HC types (Table 5.2). 
Many (22%) reported using three or more HC types (Table 5.2). Median number of HC types used was 2 
(Range: 1-6). Chronologic sequences of HC use are displayed in Figure 5.2. The most common type of 
HC used first was COCs (70%) (Table 5.2). Among these women, 42% never used another type of HC. 
Among those who used an additional HC type, the second type of HC used was commonly Depo-Provera 
(30%) or patch/ring (21%). Depo-Provera was the first HC for 20% of ever HC users (Table 5.2). Among 
these women 55% never used another type of HC. For women who used another HC type after starting 
with Depo-Provera, the most common second type was COCs (31%) or patch/ring (8%).  
Individual Timing and Duration of HC Use 
Median age at first HC use was 18 years (Table 5.2). Some (22%) experienced pregnancy prior 
to their first HC exposure, and 13% experienced their first birth prior to initiating HCs (data not shown).  
Median age at first use was lowest for COCs and Depo-Provera (Table 5.3), consistent with the 
finding that these HC types were the most common initial HCs in this cohort (Table 5.2). H-IUDs and the 
ring demonstrated a later median age of initiation (Table 5.3).  
Figure 5.3 displays HC/EC initiation relative to menarche in the SELF cohort. The curves are 
similar, with HC initiation following menarche. Median time from menarche to HC or EC initiation was 6 
years (range: -2 to 23 years). Median time from menarche to initiation was shortest for COCs and Depo-
Provera (Table 5.3). H-IUDs and the ring demonstrated a longer median time from menarche to initiation 
(Table 5.3). Alternative versions of Figure 5.3 are presented in Appendices 1.2 and 1.3. 
Median duration of HC use (sum of durations across types) was 50 months (Mean = 62 months; 
SD = 49 months; range: 1 to 237 months; Table 5.2). Duration of use was longest for COCs, Depo-
Provera, H-IUDs, and the implant (Table 5.3).  
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Reasons for HC Use 
Nearly half of ever HC users reported using HCs for non-contraceptive purposes (49%), including 
irregular menstrual cycles (40%) and heavy menstrual bleeding (22%; Table 5.4). About half (48%) of 
COC users reported non-contraceptive reasons for use, along with ~25% of patch, ring, shot, and H-IUD 
users, and 10% of implant users. Menstrual problems were reported as a reason for use by 45% of COC 
users, ~25% of ring, shot, and H-IUD users, 21% of patch users, and 7% of implant users. Seven percent 
of all HC users used HCs exclusively for non-contraceptive purposes: 11% of COC users, and 4-5% of 
users for each of the other HC types. Most (90%) implant users reported birth control as their only reason 
for use (Table 5.4).  
Sensitivity Analyses 
Since characteristics and patterns of HC use may be a function of age at enrollment and calendar 
time, we stratified our findings by time between menarche and enrollment (in three, 10-year periods: <10, 
10-19, and 20+ years) and decade of menarche (Appendices 1.4 and 1.5). Oral contraceptives remained 
the first HC type used for majority of participants, followed by Depo-Provera, regardless of menarche 
decade. Number of HC types used and total duration of HC use increased with increasing time between 
menarche and enrollment. Women whose menarche occurred closer to study enrollment were more likely 
to select “irregular periods” as a reason for use (Appendix 1.4).  
Discussion  
In this large cohort of young, black women, COCs were the most commonly used HC, despite the 
introduction of longer acting methods during that same time period.9,65 Non-contraceptive reasons for HC 
use were common, and reasons for use varied by HC type. Menstrual problems were the most frequently 
cited non-contraceptive reason for HC use. Approximately 10% of COC users used COCs for relief from 
menstrual problems exclusively.  
Our findings that COCs were the most common HC type used and were frequently used for non-
contraceptive purposes are consistent with earlier, nationally representative findings.10,11,73 It is estimated 
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that more than 1.5 million U.S. women use OCs for non-contraceptive purposes alone, most commonly to 
relieve menstrual pain and irregularity.11 
Our study had several strengths. First, we were able to assess HC use in a cohort of young, black 
women who came of age as five new HC options came to market: the implant, Depo-Provera, H-IUDs, the 
ring, and the patch. Second, we examined uptake of these new methods relative to contextual and 
individual factors: regulatory approval and menarche, respectively. Third, to our knowledge, we are the 
first to examine temporal sequencing of HC use, and to find that COCs are the most common first HC 
among women who use multiple HC types, even among those initiating HC use well after other types 
became available. Fourth, our examination of reasons for use was specific to each HC type, and 
participants could report multiple reasons for use for each type. Finally, we compared our findings to 
unpublished NSFG analyses, and considered the potential for selection bias. Given the similarity of our 
findings to national estimates, our findings are likely generalizable to the broader population of U.S. black 
women of similar age (Appendix 1.6). 
Our findings have the following limitations. First, HC data were self-reported as recalled during a 
telephone interview. Self-reported history of OC use, as collected by telephone interview, has been found 
to be reliable when compared to automated pharmacy dispensing data.61 Second, we did not have exact 
duration of use estimates for COCs or H-IUDs and had to use limited available information to estimate 
duration of use for these HC types. Third, reasons for use were self-reported and women’s definitions of 
heavy bleeding or irregular periods may vary. Finally, the data in this analysis are cross-sectional. All 
analyses, including Figures 5.1-5.3, relied on retrospectively recalled data. 
To our knowledge, this is the first study to examine timing of HC initiation relative to menarche 
(Table 5.3 and Figure 5.3). Timing of HC initiation relative to menarche could be a meaningful marker for 
the developmental timing of HC exposure. Future research could consider the effect of this timing on 
gynecological health endpoints, including fibroids. 
The emphasis of most public health research and interventions regarding HCs to date has been 
on pregnancy prevention. Our finding that a sizeable proportion of women used HCs for non-
contraceptive purposes are reinforced by prior, nationally representative findings11 and point to HCs as 
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important for management of conditions that affect quality of life. Further research could explore clinical 
factors and patient preferences underlying HC selection, particularly for non-contraceptive purposes.  
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Table 5.1. Characteristics of 1,693 women who enrolled in SELF in 2010-2012 (Detroit, MI, USA) 
 Overall Never used HCs Ever used HCs* 
 N=1,693 N=238 N=1,455 
 n (%) n (%) n (%) 
Age at enrollment (years)    
     23 – 26  519 (31) 98 (41) 421 (29) 
     27 – 30  581 (34) 83 (35) 498 (34) 
     31 – 35  593 (35) 57 (24) 536 (37) 
    
Annual household income†    
< $20,000 766 (45) 123 (52) 643 (44) 
$20,000 to $50,000 628 (37) 73 (31) 555 (38) 
> $50,000 287 (17) 39 (17) 248 (17) 
    
Education‡    
HS/GED or less 369 (22) 69 (29) 300 (21) 
Some college/associates/technical 848 (50) 107 (45) 741 (51) 
Bachelors/masters/PhD 475 (28) 62 (26) 413 (28) 
    
Body mass index (kg/m2)    
     < 25 335 (20) 50 (21) 285 (20) 
     25-29 350 (21) 32 (13) 318 (22) 
     30-34 328 (19) 45 (19) 283 (19) 
     > 35 680 (40) 111 (47) 569 (39) 
    
Smoking history    
Never smoked 1,245 (74) 168 (71) 1,077 (74) 
Former smoker 125 (7) 16 (7) 109 (7) 
Current smoker (< 10 years) 238 (14) 41 (17) 197 (14) 
Current smoker (> 10 years) 85 (5) 13 (5) 72 (5) 
    
Age at menarche    
      < 10 years 310 (18) 39 (16) 271 (19) 
     11 334 (20) 48 (20) 286 (20) 
     12 458 (27) 68 (29) 390 (27) 
     13 286 (17) 42 (18) 244 (17) 
     > 14 years 305 (18) 41 (17) 264 (18) 
    
Heavy menstrual bleeding (HMB)    
     History of heavy (gushing) menstrual bleeding§ 625 (37) 80 (34) 545 (37) 
     Talked to doctor about HMB 338 (20) 34 (14) 304 (21) 
    
Age at first sex||    
     Never had sex 35 (2) 26 (11) 9 (1) 
     < 14 years 239 (14) 17 (7) 222 (15) 
     14-17 1,036 (61) 120 (50) 916 (63) 
     18-21  332 (20) 58 (24) 274 (19) 
     > 21 years 49 (3) 17 (7) 32 (2) 
    
Reproductive history    
     Never pregnant 451 (27) 124 (52) 327 (22) 
     Parous 1,031 (61) 81 (34) 950 (65) 
          1 birth 432 (26) 39 (16) 393 (27) 
          2 births 313 (18) 18 (8) 295 (20) 
          3+ births 286 (17) 24 (10) 262 (18) 
    
Emergency contraception (EC)    
     Ever used EC 402 (24) 39 (16) 363 (25) 
*HC use prior to (and during) enrollment in SELF. Includes combined oral contraceptives (COCs), the patch, the 
ring, Depo-Provera, hormonal intrauterine devices (H-IUDs), the implant, and the mini-pill (progestin-only pill). Non-
hormonal IUDs and emergency contraceptives are not included.  
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†Annual household income was missing for n=12 participants. 
 
‡Education was missing for n=1 participants. 
 
§“The next questions are about heavy, gushing (GUH-shing) type menstrual bleeding that was too much for your 
pads or tampons to absorb, even when changed frequently. Have you ever had heavy, gushing type bleeding?” 
 
||Age at first sex was missing for n=2 participants. 
 
Abbreviations: EC, emergency contraception; HCs, hormonal contraceptives; HS, high school graduate; GED, 
general education development; HMB, heavy menstrual bleeding; PhD, doctor of philosophy; SELF, Study of 




Table 5.2. Characteristics of hormonal contraceptive (HC)* use in 1,455 ever HC users who enrolled in 
SELF in 2010-2012 (Detroit, MI, USA) 
 n (%) 
Ever use of HCs by type 1,455 (100) 
Estrogen-containing   
     Any route 1,272 (87) 
     Combined oral contraceptives (COCs) 1,185 (81) 
     Patch 303 (21) 
     Ring 227 (16) 
Progestin-only contraceptives  
     Any route 864 (59) 
     Depo-Provera 720 (49) 
     Hormonal intrauterine device (H-IUD) 177 (12) 
     Implant 42 (3) 
     Mini-pill 77 (5)  
          Mini-pill and COC's 64 (4) 
          Mini-pill only 13 (1) 
  
Hormonal contraceptives currently in use at enrollment‡ 469 (100) 
Estrogen-containing   
     Any route 237 (51) 
     Combined oral contraceptives (COCs) 200 (43) 
     Patch 6 (1) 
     Ring 31 (7) 
Progestin-only contraceptives  
     Any route 234 (50) 
     Depo-Provera 100 (21) 
     Hormonal intrauterine device (H-IUD) 120 (26) 
     Implant 13 (3) 
     Mini-pill 1 (0) 
  
Number of HC types* ever used 1,455 (100) 
     1  617 (42) 
     2  510 (35) 
     3  238 (16) 
     > 4 90 (6) 
  
First hormonal contraceptive type used§ 1,412 (100) 
Estrogen-containing   
     Any route 1,077 (76) 
     Combined oral contraceptives (COCs) 993 (70) 
     Patch 66 (5) 
     Ring 18 (1) 
Progestin-only contraceptives  
     Any route 335 (24) 
     Depo-Provera 278 (20) 
     Hormonal intrauterine device (H-IUD) 15 (1) 
     Implant 12 (1) 
     Mini-pill 30 (2) 
  
Age at first HC* use (years)|| 1,454 (100) 
     < 17 520 (36) 
     17 – 20  643 (44) 
     > 21 291 (20) 
  
Total duration of HC use (complete years)*¶ 1,452 (100) 
     < 2 541 (37) 
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     3-4 253 (17) 
     5-6 219 (15) 
     7-8 163 (11) 
     > 8 276 (19) 
*Includes combined oral contraceptives (COCs), the patch, the ring, Depo-Provera, hormonal intrauterine devices 
(H-IUDs), the implant, and the mini-pill (progestin-only pill). Non-hormonal IUDs and emergency contraceptives are 
not included.   
 
†Women who used progestin-only methods and never used an estrogen containing method. 
 
‡Some women (n=2) used two HC methods simultaneously at enrollment. 
 
§Excludes n=43 women for whom order of use for first and second HC types could not be determined. For women 
who used EC before other HC types (n=43), EC was discarded and the next HC type was counted as the first HC 
type when generating this list.  
 
||Age at first HC use was missing for n=1 individual.   
 
¶Duration of use was missing for n=1 patch user and n=2 pill users. 
 
Abbreviations: COCs, combined oral contraceptives; HC, hormonal contraceptives; H-IUD, hormonal intrauterine 




Table 5.3. Age at first HC use, time from menarche to initiation, and duration of use by hormonal 
contraceptive type in 1,455 ever HC users* who enrolled in SELF in 2010-2012 (Detroit, MI, USA) 
 Age at first use† Years since menarche‡ Total months used§ 
 Median (IQR) Median (IQR) Median (IQR) 
Estrogen-containing Types    
   COC (n=1,185) 18 (16, 20) 6 (4, 8) 24 (10, 61) 
   Patch (n=303) 21 (19, 23) 9 (7, 11) 12 (3, 24) 
   Ring (n=227) 24 (21, 26) 12 (10, 14) 8 (3, 18) 
Progestin-only Types    
   Shot (n=720) 19 (17, 22) 7 (5, 10) 24 (7.5, 48) 
   H-IUD (n=177) 25 (23, 28) 14 (11, 17) 24 (12, 36) 
   Mini-Pill (n=77) 21 (17, 25) 9 (5, 13) 12 (4, 24) 
   Implant (n=42) 22 (19, 26) 10 (5, 15) 23 (12, 48) 
   EC (n=402)|| 23 (20, 26) 11 (8, 14) 1 (1, 2) 
*Includes combined oral contraceptives (COCs), the patch, the ring, Depo-Provera, hormonal intrauterine devices 
(H-IUDs), the implant, and the mini-pill (progestin-only pill).  
 
†Age at first use was missing for n=1 COC users, n=1 patch users, and n=1 shot users. Up to 2% (n=24) of age at 
first COC use reported in this table could represent age at first mini-pill use. 
 
‡Calculated by subtracting age at menarche from age at first use. 
 
§Duration of use was missing for n=1 patch user and n=2 pill users. For ECs, number of times took ECs is reported 
instead. 
 
||Includes n=39 women who used EC only, plus n=363 women who used ECs in addition to COC, the patch, the 
ring, Depo-Provera, H-IUD, implant, or mini-pill.  
 
Abbreviations: COC, combined oral contraceptive; EC, emergency contraception; HC, hormonal contraceptive; 
H-IUD, hormonal intrauterine device; IQR, interquartile range; NA, not applicable; SELF, Study of Environment, 




Table 5.4. Reasons for use, by HC type, in 1,455 ever HC users who enrolled in SELF in 2010-2012 
(Detroit, MI, USA) 
  Estrogen-containing  Progestin-only 
Reason for Use* Total COCs† Patch‡ Ring  Shot H-IUD Implant 
 (n=1,455) (n=1,185) (n=302) (n=227)  (n=720) (n=177) (n=42) 
Contraceptive Reasons         
Birth control  1,357 (93) 1,051 (89) 286 (95) 219 (96)  685 (95) 170 (96) 42 (100) 
   Birth control only 745 (51) 619 (52) 229 (76) 165 (73)  520 (72) 130 (73) 38 (90) 
         
Non-contraceptive Reasons         
Non-contraceptive reasons 
only§ 
98 (7) 134 (11) 16 (5) 8 (4)  34 (5) 7 (4) 0 (0) 
Menstrual problems|| 671 (46) 529 (45) 63 (21) 57 (25)  186 (26) 47 (27) 3 (7) 
   Menstrual problems only§ 79 (5) 107 (9) 9 (3) 8 (4)  26 (4) 5 (3) 0 (0) 
   Irregular cycles 587 (40) 465 (39) 52 (17) 50 (22)  159 (22) 37 (21) 2 (5) 
Heavy bleeding 323 (22) 267 (23) 21 (7) 13 (6)  77 (11) 28 (16) 2 (5) 
Menstrual pain 255 (18) 202 (17) 23 (8) 16 (7)  70 (10) 16 (9) 1 (2) 
Other¶ 100 (7) 76 (6) 8 (3) 8 (4)  15 (2) 3 (2) 1 (2) 
*Women could report multiple reasons for use. 
 
†Reason(s) for use for oral contraceptives could not be stratified by mini-pill versus combined oral contraceptives for 
women who had used both types (n=64, 5% of pill users); few used only the mini-pill, n=13, so no data are shown for 
mini-pill. 
 
‡Reasons for use data were missing for n=1 patch user. 
 
§To the exclusion of all other reasons for use, by HC type. For the “Total” column and “Non-contraceptive reasons only” 
row, the participant could not have used any type of HC for contraceptive purposes, ever. For the “Total” column and 
“Menstrual problems only” row, participants could not have ever used any type of HC for reasons other than irregular 
cycles, heavy bleeding, or menstrual pain. 
 
||Includes irregular cycles, heavy bleeding, or menstrual pain.  
 
¶Other non-contraceptive reasons included acne, endometriosis, menstrual migraines/headaches, premenstrual 
syndrome (PMS), premenstrual dysphoric disorder (PMDD), polycystic ovary syndrome (PCOS), and ovarian cysts. 
 





Figure 5.1. Annual initiation rates (with 95% CIs) for seven HC types and emergency contraception in 
1,693 women who enrolled in SELF in 2010-2012 (Detroit, MI, USA)*†‡ § || 
 
*For each year and hormonal contraceptive type, Rate = number of women who recalled initiating the given HC type in 
that year, divided by the number of women who had reached menarche by that year and had not yet initiated that HC 
type. 
†Excluded from this figure are 6 women who used a hormonal contraceptive prior to menarche (n=5) or were missing 
age-at-first-use data (n=1).  
‡Data not shown before 1990 or after 2010 due to sparsity.  
§Dashed lines represent estrogen-containing HCs (COC, patch, ring). Dotted line represents EC. 
||Up to 2% (n=24) of COC initiation depicted in this figure could represent mini-pill initiation.  
Abbreviations: CIs, confidence intervals; COCs, combined oral contraceptives; EC, emergency contraception; HC, 







Figure 5.2. Sankey* diagram depicting self-reported HC sequences of use in 1,405 women who enrolled in 
SELF in 2010-2012 (Detroit, MI, USA) (represents utilization occurring in 1988-2012)†‡§ 
 
First HC                               Second HC                                  Third HC                                   Four + HCs                            Stop/End||
 
 
First HC                               Second HC                                  Third HC                                   Four + HCs                            Stop/End||
 
 
*A Sankey diagram is a flow diagram, in which the width of the bands are proportional to the quantity (in this case, 
people) in that band. For example, far more women in the SELF cohort used COC followed by the Patch/Ring than had 
used H-IUD/Implant followed by COC. The depicted changes in HC could have occurred immediately or could have 
been separated by long periods of time without HC, and may have included intervening pregnancies.  
 
†Excludes n=50 women for whom order of use could not be determined: n=43 women for whom order of use for the first 
two HC types could not be determined, and n=7 women for whom order of use of later types could not be determined.  
 
‡“Mini-pill” refers to progestin-only oral contraceptives.  
 
§Repeat use of the same method is not depicted. For instance, Patch/Ring to Patch/Ring represents a change between 
the patch and the ring. Similarly, H-IUD/Implant to H-IUD/Implant represents a change from H-IUD to implant, or from 
implant to H-IUD. 
 
||“Stop/End” refers to the end of the recorded history and includes current users. For example, a woman who is 
currently using the patch will appear in one of the lines that goes straight from “Patch/Ring” to “Stop/End.”  
 
Abbreviations: COC, combined oral contraceptive; HC, hormonal contraceptive; H-IUD, hormonal intrauterine device; 
















Four or more 
Mini-pill 
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Figure 5.3. Cumulative incidence curves (with 95% CIs) for menarche and HC/EC initiation, by year, in 
1,693 women who enrolled in SELF in 2010-2012 (Detroit, MI, USA) 
 
Abbreviations: CIs, confidence intervals; EC, emergency contraception; HC, hormonal contraceptive; SELF, 
Study of Environment, Lifestyle, and Fibroids. 
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CHAPTER 6: COMBINED ORAL CONTRACEPTIVE UTLIZATION AND UTERINE FIBROID 
PREVALENCE AND INCIDENCE IN THE SELF COHORT (PAPER 2) 
Introduction 
More than 1 billion U.S. dollars are spent each year to treat uterine fibroids (benign tumors of the 
uterus).1 Fibroid symptoms include pelvic pressure, pain, and heavy menstrual bleeding leading to iron 
deficiency anemia.4 Fibroids can cause infertility and obstetric complications, and may be associated with 
preterm delivery.4,5 In the U.S., black women experience greater risk of, and a 10-year earlier onset of, 
fibroids than white women, and their fibroids are more severe.2 At least 80% of black women will develop 
uterine fibroids in their lifetime.3  
While a great deal is already known about how to identify and treat symptomatic uterine fibroids, 
considerably less is known about fibroid prevention. This is surprising given the high prevalence and 
public health burden of the disease. 
It is currently thought that estrogen and progesterone have complex, interrelated roles in fibroid 
tumor development.6,7 Progesterone appears to cause fibroid growth, and estrogen increases availability 
of progesterone receptors.7 Yet, injectable progesterone may offer lasting protection against uterine 
fibroids,50 and oral doses of these hormones are commonly used as a first-line treatment for fibroid 
symptoms.23  
Oral contraceptives (OCs) are generally composed of both estrogen and progestin (synthetic 
progestogen).8 Exposure to OCs is widespread in the U.S.9–11 Among sexually experienced black women 
aged 15-44, 80% have used OCs in their lifetime.9 Despite the availability of longer acting methods in the 
U.S., OCs remain the most commonly used form of hormonal contraception.41  
The data on oral contraceptives and fibroid risk have been mixed, with some studies suggesting a 
detrimental effect if taken early in life,12,13 and others suggesting a protective effect14–16 or no effect at 
all.17–20 Studies of OC use and fibroid development to date have lacked baseline fibroid assessments and 
were unable to establish temporality of OC use and fibroid occurrence. Furthermore, fibroid assessment 
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was most often by clinical recognition; i.e., only women who sought treatment for fibroid symptoms and 
who had access to care were screened. Thus, the resulting associations may have been biased by 
factors related to clinical or surgical detection, including perception of symptoms and access to medical 
treatment.2 Majority of studies to date examined OC use and fibroids in all white or mostly white women, 
despite the fact that black women are much more likely to be affected by the condition. Finally, existing 
studies of OC use and fibroid incidence have yet to employ propensity score based methods and 
counterfactual thinking. 
We addressed the longstanding question of how oral contraceptive use influences uterine fibroid 
development using data from the Study of Environment, Lifestyle & Fibroids (SELF) – the first 
prospective, ultrasound-based study specifically designed to capture uterine fibroid incidence in young, 
black women. Specifically, we examined the associations between different levels of COC use and (a) 
prevalent fibroids at baseline and (b) incident fibroids at ~40 months of follow-up. 
Methods 
Study population  
The Study of Environment, Lifestyle & Fibroids (SELF) is a prospective cohort study of 1,693 
young (23-35 years), African American women living in the Detroit, Michigan area. SELF was designed to 
investigate risk factors for uterine fibroid incidence and growth.2,21,22 Recruitment and baseline data 
collection were completed in 2010-2013.50 Participants were recruited from the Detroit area via local radio 
and television commercials, advertisements in newspapers and magazines, brochures at healthcare 
clinics, information booths at community events, and via the Henry Ford Health System (HFHS).2 The 
primary eligibility requirements were age, self-identified African American/black, and having no prior 
clinical diagnosis of uterine fibroids. The retention rate for SELF was high at >85% for the 40-month 
follow-up.  
SELF was approved by the institutional review boards of the National Institute of Environmental 






Fibroid identification was performed using transvaginal ultrasonography (TVUS). All exposure and 
covariate data were self-reported, with the exception of BMI, which was calculated using height and 
weight as measured at the baseline clinic visit. 
Hormonal contraceptive use 
As part of participation in SELF, history of hormonal contraceptive (HC) use was collected via 
telephone interview as part of an enrollment questionnaire. Women were asked if they had ever used 
each of the following types of HC: “birth control pills” (OCs), “mini-pill” (progestin-only OCs), hormonal 
implant, hormonal patch, vaginal ring, “hormone shots like Depo-Provera,” and hormonal intrauterine 
devices (H-IUD). Brief descriptions and examples of common brand names were provided for hormonal 
implants and shots.   
For each HC type (and separately for each H-IUD), women were asked about their age at first 
use, whether or not they were currently using, how old they were when they stopped using, and their 
reason(s) for using. For age at first use, women were asked, “How old were you when you started using 
birth control pills, whether or not it was to prevent pregnancy?” Women who had used OCs were asked 
whether or not they had ever stopped using for a month or longer, and if so, the proportion of time 
between start and stop that they spent on OCs (“very little of that time,” “less than half of that time,” 
“about half,” “more than half,” “most of that time,” “the entire time”). Women who used the “mini-pill,” 
implant, patch, ring, or shot were asked to state the total number of months and years that they had used 
each method prior to study enrollment.  
Uterine fibroids  
Fibroid identification was performed as previously described25 using transvaginal ultrasonography 
(TVUS) – the current standard of care for uterine fibroid assessment.62 TVUS has 99% sensitivity and 
91% specificity (relative to histology) for detecting uterine fibroids.63 SELF sonographers were specially 
trained, registered diagnostic sonographers with at least 3 years of experience in gynecologic 
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sonography.2 All sonographers were given additional, study specific training.2 Fibroids were carefully 
mapped, measured, and numbered on a standardized form.2 Each fibroid was measured 3 times in 3 
perpendicular planes, resulting in 9 diameter measurements for each fibroid at each visit.25 Quality control 
procedures were carried out.2 The head sonographer reviewed still and video images for 8% of each 
sonographer’s examinations each month. It is estimated that 98.5% of women considered fibroid free at 
baseline were truly fibroid free, and 99.6% of women with fibroids at baseline truly had fibroids.2  
Exposure and outcome classification 
Ever use and age at first use of COCs 
Women who reported using “the pill” were considered to have used combined oral contraceptives 
(COCs) if they answered “No” or “I don’t know” to “Have you ever used a progesterone-only  birth control 
pill, or “mini-pill”, such as Micronor, Nora-BE, or Ovrette?” Age at first COC use was dichotomized into 
<17 and >17 based on findings in previous literature suggesting that COC initiation prior to age 17 years 
may be associated with fibroid development later in life.12,13 
Duration of use for COCs  
For the purposes of this study, “duration of use” refers to cumulative lifetime exposure from birth 
until study enrollment. We used women’s self-reported ages of first and last COC use to approximate 
duration of use. Many women reported stopping use of COCs for one month or more, and were asked to 
answer a question regarding the proportion of time between start and stop age that they had been using 
COCs. Using these data, duration of use estimates for combined oral contraceptives (COCs) were 
calculated in three steps, as follows: (1) Subtract age at first OC use from age at last OC use, or age at 
enrollment for current users, (2) Subtract months and years on the mini-pill, (3) Multiply by the proportion 
of time spent using OCs. Weights were applied as follows: 10% for “very little of that time,” 25% for “less 
than half of that time,” 50% for “about half,” 75% for “more than half,” 90% for “most of that time,” and 
100% for “the entire time.” When age at first use and age at last use were identical, a duration of 6 
months was assigned.  
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Time since last use of COCs 
For past COC users, time since last COC use was calculated by subtracting self-reported age at 
last pill use from age at enrollment. Current users were assigned a time since last use value of 0. For 
n=64 women who used both combined and progestin-only OCs, time since last COC use specifically 
could be determined for 31 subjects. Time since last use of COCs could not be determined for the 
remaining 33 women due to the structure of the enrollment questionnaire, which did not initially 
distinguish between COCs and progestin-only pills. These were women who provided the same 
discontinuation age for both OCs and progestin-only OCs, but who had used both COCs and progestin-
only OCs. 
Joint duration of and time since last use 
Duration of use was characterized as short (< 2 years) or long (> 2 years). Time since last use 
was characterized as recent (< 5 years) or past (> 5 years). 
Uterine Fibroids 
Women were considered positive for uterine fibroids if they had one or more lesions of at least 
0.5 cm maximum diameter that could be visualized in all three planes, as previously described.25  
Prevalence study design 
First, we examined the association between ever COC use and prevalent fibroids at baseline. 
This cross-sectional analysis included all women enrolled in SELF. Subsequently, we examined the 
associations between prevalent fibroids and each of four exposures: age at first use, duration of COC 
use, time since last COC use, and joint duration of and time since last COC use. These analyses were 
restricted to COC users, comparing each category of use to the lowest level. 
Incidence study design 
Second, we carried out incidence analyses analogous to the prevalence analyses just described. 
This allowed us to examine the associations between incident fibroids and different levels of COC use. To 
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establish temporality, women were included in our incidence analyses if their baseline ultrasound showed 
no fibroids.  
SELF included baseline ultrasounds and three follow-up ultrasounds for all participants. Follow-up 
ultrasounds took place at ~20 months, ~40 months, and ~60 months. Ultrasound data were available for 
the first two follow-up visits at the time of this analysis. We examined cumulative incidence at ~40 months 
of follow-up. Women were considered outcome positive if their ~20-month or ~40-month ultrasounds 
revealed uterine fibroids. 
Flow diagrams depicting inclusion and exclusion criteria for our incidence analyses appear in 
Appendix 2.1. Women were considered to have missing outcomes if ultrasound data were not available 
for both follow-up study visits. Additionally, women were also considered to have missing outcomes if 
their ~20-month ultrasound was negative for fibroids and no ~40-month ultrasound data were available. 
This was done since their cumulative fibroid status at 40 months was unknown. Reasons for missing 
follow-up ultrasounds are quantified in Appendix 2.1 and included hysterectomy, uterine surgery, and 
inability to adequately visualize the uterus. Individuals with missing outcomes were included in our 
propensity score calculations, and inverse probability of censoring (i.e., missing outcomes) weights were 
applied in order to upweight similar individuals in the calculations of our risk ratio estimates (see Appendix 
2.2). 
Statistical analyses 
All data management and analyses were performed in SAS 9.4 (SAS Institute, Cary, NC, USA). 
We report our propensity score (PS) based methods in accordance with the recommendations provided 
by Ali et al. (2014)74 in the Journal of Clinical Epidemiology in Appendix 2.2. In brief, inverse probability 
(IP) weights were constructed for all exposures, and censoring. Standardized mortality ratio (SMR) type 
weights were constructed for ever COC use, i.e., the weights for the ever-never use analyses were based 
upon the covariate distribution of the “treated,” in this case, the “ever users.” For incidence analyses, the 
IP and SMR weights were multiplied by the inverse probability of censoring weights. Weighted log-
binomial regression models were used to estimate prevalence ratios and risk ratios for uterine fibroids. No 
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additional covariates were included in the weighted models. Confidence intervals for weighted models 
were generated using robust variance (“sandwich”) estimator by use of the SAS REPEAT statement. 
The covariate set for all weight calculations were measured at baseline (and thus not time-varying 
in this analysis) and included: age in years (continuous), age at menarche (<11 years), Depo-Provera 
duration of and time since last use (never use, short/past, long/past, short/recent, long/recent), total 
implant and H-IUD duration of use (>24 months), time since last birth (<5 years, 5-9.99 years, >10 years 
and no birth), parity (nulliparous, 1-2 births, >3 births), BMI (>30, remaining values according to tertile), 
and education (Bachelor’s degree or higher). In addition to these covariates, censoring weights also 
included the exposure of interest, annual household income (<$20,000, $20,000-49,999, and >$50,000 ), 
baseline employment status (not employed, employed <30 hours per week, employed >30 hours per 
week), smoking history (never smoked, former smoker, current smoker of <10 years, current smoker of 
>10 years) and history of heavy “gushing” type menstrual bleeding (yes/no). 
Results 
Study population 
Median age at enrollment for the entire cohort was 29 years [IQR: 26, 32]. Age did not differ 
appreciably between COC users and never-users, but was slightly higher among women with prevalent 
fibroids (Table 6.1). The majority (83%) of women participating in SELF had an annual household income 
of less than $50,000 per year. Income distribution appeared lower among never COC users as compared 
to ever users, and higher among women with prevalent fibroids as compared to women without. Most 
(62%) of the women were employed, and employment appeared more common among ever COC users 
and those with prevalent fibroids. Approximately 28% of SELF participants had earned at least a 
Bachelor’s degree. Bachelor’s or higher educational attainment was more common among the ever COC 
users and women with prevalent fibroids.  
Overweight (21%) and obesity (60%) were common in this cohort, and did not appreciably vary 
by COC use or uterine fibroid status. Approximately 26% of the women were ever-smokers, and current 
smoking was more frequent among women who had never used COCs.  
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Median age at menarche was 12 years, with only 18% reporting onset of menses prior to age 11. 
Earlier menarche was more common among women with prevalent fibroids. Nearly 37% of the cohort 
experienced heavy “gushing” type menstrual bleeding. Heavy “gushing” type bleeding was more frequent 
among ever COC users and those with prevalent fibroids at baseline. Approximately 60% of the cohort 
had given birth. Birth was more common among ever COC users and women without prevalent fibroids. 
Approximately one-third (32%) of the cohort had given birth within the last 5 years. Birth was more recent 
for those without prevalent fibroids (Table 6.1). 
About 42% of the cohort had used Depo-Provera. Depo-Provera use was less common among 
women with prevalent fibroids (Table 6.1). Only 7% of SELF participants had used the patch or a 
hormonal intrauterine device (H-IUD) for 24 months or longer in total. Patch and H-IUD use did not differ 
appreciably by COC use or baseline fibroid status, though appeared less common among women with 
prevalent fibroids (Table 6.1).  
Exposure and outcome prevalence 
Nearly 70% of SELF participants reported a history of COC use (Table 6.2). Of those who did not 
report a history of COC use, 53% had used another HC, principally Depo-Provera (41%). Of the 1,185 
women who reported COC use, 35% reported initiating COCs prior to age 17 (Table 6.2). Most (73%) 
used COCs for less than 5 years in total. Relatively few (23%) were currently using COCs at study 
enrollment. Nearly half (48%) had used COCs 5 or more years ago (Table 6.2). Uterine fibroids were 
detected in 23% (n=385) of baseline ultrasounds. Among women who were fibroid-free at baseline 
(n=1,308), 17% (n=221) developed fibroids by ~40 months of follow-up. 
Prevalence Findings 
Main findings 
We observed no association between ever use of COCs and fibroid prevalence (Table 6.2, Figure 
6.1). Similarly, we observed no association between COC initiation prior to age 17 and fibroid prevalence, 
among COC users. Comparing each level of duration of COC use to < 1 year of use, weighted prevalence 
ratios varied from 0.88 to 1.15. Weighted prevalence ratios (wPR) comparing each level of time since last 
use to current use ranged from 1.13 to 1.45, declining with increasing time since last use. All estimated 
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associations were null, with the possible exception of COC use 1-2 years ago (wPR: 1.45; 95% 
confidence interval: 1.00, 2.10). Multivariable log-binomial regression results are presented alongside 
weighted estimates in Table 6.2 and were found to be similar.  
Sensitivity analyses  
We re-ran our ever COC use weighted analysis to determine what influence, if any, the 
composition of the “Never” comparator group had on our findings. When the “Never” group was restricted 
to women who had never used any form of hormonal contraception (HC), a possible protective 
association emerged (wPR: 0.83; 95% confidence interval: 0.65, 1.06). When the “Never” group was 
restricted to ever HC users, our findings were null (wPR: 0.93; 95% confidence interval: 0.68, 1.27). 
Incidence Findings 
Main findings 
At ~40-months’ follow-up, we observed a possible protective association between ever use of 
COCs and fibroid cumulative incidence among women who were without fibroids at study enrollment 
(Table 6.3, Figure 6.2). The weighted risk ratio comparing ever to never COC use was 0.78 (95% 
confidence interval: 0.60, 1.00). However, all estimated associations among COC users did not suggest a 
discernable pattern of harm or protection. Our age at first use estimates showed no strong association 
between COC initiation prior to age 17 and fibroid incidence among COC users. Comparing each level of 
duration of COC use to < 1 year of use, weighted risk ratios varied from 1.10 to 1.49, with overlapping 
confidence intervals ranging from 0.69 to 2.38. Weighted risk ratios (wRR) comparing each level of time 
since last use to current use ranged from 0.87 to 1.23, declining with increased time since last use, with 
overlapping confidence intervals ranging from 0.50 to 2.10. Multivariable log-binomial regression results 
were similar to weighted estimates (Table 6.3).  
Sensitivity analyses 
When restricting the “Never” comparator group to ever HC users, the observed association 
between COC use and fibroid incidence disappeared (wRR: 0.92, 95% CI: 0.60, 1.40). The association 
re-emerged when restricting the “Never” comparator group to women with no history of HC use (wRR: 
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0.72; 95% CI: 0.51, 1.01). We also examined 20-month incidence of fibroids and noted a possible 
protective association for ever-COC use, and time since last use 5 or more years ago (Appendix 2.7.3). 
When multi-level outcome models were implemented with parity and uterine fibroid incidence as a single 
joint outcome, all associations were null. Potentially protective associations were observed for ever COC 
use and the incident fibroids, regardless of childbirth during follow-up (Appendix 2.7). The direction of the 
association between fibroid incidence and later age of COC initiation was reversed when birth was 
considered, such that a protective association was observed for the joint outcome of incident fibroids and 
childbirth during follow-up, while a harmful association was apparent for incident fibroids and no childbirth 
during follow-up. For instance, women who initiated COC use at age 17 or older experienced 0.47 times 
the odds of developing a fibroid and giving birth during follow-up as women who initiated COC use prior to 
age 17 (95% CI: 0.11, 2.00; Appendix 2.7.2). When pregnancy and Depo-Provera use during follow-up 
were added to the IP and censoring weighted incidence models, results did not noticeably differ from 
those in our main analysis (Appendix 2.7.1).  
Discussion 
In this study of 1,693 young, black women living in Detroit, we found that ever use of COCs might 
be protective against uterine fibroids when compared to use of no hormonal contraceptives (HCs) at all. 
This protective association disappeared when comparing COC users to ever-users of any other HC type, 
suggesting that HC and not necessarily COC use may be protective against uterine fibroids. Four prior 
studies reported odds ratios (OR) comparing ever to never oral contraceptive users.14,17,18,48 Lumbiganon 
et al. (1995)48 reported a protective association of OR = 0.76 (95% CI: 0.66-0.92). This is similar to our 
incidence wRR of 0.78 (95% CI: 0.60, 1.00). Three other studies reported null findings.14,17,18 It is unclear 
whether women in the “Never” comparison groups for these four studies had used other HCs. All four 
studies were case-control studies in which cases were defined as surgically treated leiomyomas and 
controls were other hospitalized patients. None of the four studies reported on race, with the exception of 
Lumbiganon et al. (1995)48 in which <1% of study participants were neither Thai nor Chinese. All four 
studies were conducted at least 20 years ago in Italy14,17,18 or Thailand,48 where oral contraceptive 
formulations were likely different from the ones used by women in SELF. It is difficult to make direct 
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comparisons between our work and others’ due to these differences in time period, population, and study 
design. 
While two prior studies reported a harmful association between COC initiation before age 17 
years,12,13 we did not observe this association in our data. While these studies compared each age at first 
use category to never users, our age at first use comparisons were restricted to ever COC users. One 
study26 found no association between age at OC initiation and uterine fibroids when comparing OC 
initiation before and after age 17 among ever OC users, similar to our study. However the reported 
association (OR: 1.12: 95% CI: 0.57, 2.18) was unadjusted.26  
Though our study design and population differed considerably, our null findings for duration of 
use and time since last use of COCs are in concurrence with most prior literature,12,13,15–18,20 including the 
Black Women’s Health Study (BWHS).12 However, three studies did report a protective association for 
longer duration of use of OCs,14,15,49 and one study reported that longer time since last OC use (> 5 year 
versus < 5 years) was associated with uterine fibroid prevalence (unadjusted p < 0.01).49 Never users 
served as the referent for two of these three studies,14,15 and the third study did not report adjusted 
associations.49 Black women were not represented in these studies which took place in Italy during the 
1990s14,49 or among contracepting, married white women in England or Scotland in 1968-1985.15  
Strengths and limitations 
Ours was the first prospective, ultrasound-based study to examine the association between COC 
use and uterine fibroids in young, black women. SELF performed ultrasounds in all study participants, 
including at baseline and follow-up, regardless of symptoms or health care access. Incidence analyses 
were restricted to women without fibroids at baseline, strengthening the temporality75 basis of our 
observed associations. Use or propensity score (PS) based methods allowed for greater transparency 
and interpretability of our findings. We are the first study to examine COC use and uterine fibroid 
outcomes using PS-based methods. Prior studies used multivariable regression models and most often 
compared different levels of COC user to never users, which may not be the most relevant comparison as 
women are unlikely to choose between a specific level of COC use (e.g., duration of use 3-4 years) and 
never using COCs at all. Analogous to the counterfactual conundrum of smoking, we are unlikely to ever 
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live in a world in which no women ever use COCs. Therefore, our within-COC users comparisons are 
likely to be more relevant to prescribers, patients, and policymakers.  
Our findings should be considered in light of our study’s limitations. First, we did not have 
adequate statistical power to rule out small associations.76 The estimates reported are measures of 
association from a single cohort study and should be considered in context of a broader literature base. 
Second, all exposure and covariate data with the exception of BMI were self-reported. Self-reported 
history of OC use, as collected by telephone interview, has been found to be reliable when compared to 
automated pharmacy dispensing data 61.  Third, we did not have exact duration of use estimates for 
COCs or H-IUDs and had to use limited available information to estimate duration of use for these HC 
types. Finally, women with prior clinical diagnosis were excluded from participating in SELF. While 
exclusion of women with clinical diagnosis of fibroids may have resulted in selection bias, only 5.87% 
(95% CI: 4.32, 7.42) of U.S. black women aged 23-35 in 2011-2013 had ever been diagnosed with 
uterine fibroids, and the possible selection bias is expected to be small (unpublished analysis).77–79  
Conclusion 
Ever use of COCs may be protective against uterine fibroid development, though no more 
protective than other HC types. It is unclear how differing levels of COC use among COC users might 
confer differing levels of protection or harm, if any. Further studies may be warranted in larger cohorts that 
would lead to estimates that are more precise and that build upon the methodological improvements 
represented by this study. The findings from these analyses contribute to the evidence base for oral 
contraceptive safety and effectiveness, allowing providers and patients to make better, evidence-based 
decisions regarding oral contraception in women with or without fibroids.  
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Table 6.1. Characteristics of 1,693 women who enrolled in SELF in 2010-2012 (Detroit, MI, USA) 
 COC use  Uterine fibroids at baseline 
 Never Ever  No Yes 
 N=508 N=1,185  N=1,308 N=385 
 n (%) n (%)  n (%) n (%) 
Age at enrollment (years)      
     Median [IQR] 28 [25, 31] 29 [26, 32]  28 [25, 31] 30 [28, 33] 
      
Annual household income*      
< $20,000 288 (57) 478 (41)  607 (47) 159 (41) 
$20,000 to $50,000 146 (29) 482 (41)  489 (38) 139 (36) 
> $50,000 70 (14) 217 (18)  201 (15) 86 (22) 
      
Baseline employment status*      
     Not employed 231 (45) 409 (35)  518 (40) 122 (32) 
     Employed, but less than 30 hrs/wk 68 (13) 142 (12)  172 (13) 38 (10) 
     Employed, 30 or more hrs/wk 209 (41) 630 (53)  615 (47) 224 (58) 
      
Education*      
Bachelors/master’s/PhD 110 (22) 365 (31)  336 (26) 139 (36) 
      
Body mass index (kg/m2)      
     < 25 107 (21) 228 (19)  260 (20) 75 (19) 
     25-29 101 (20) 249 (21)  279 (21) 71 (18) 
     > 30 300 (59) 708 (60)  769 (59) 239 (62) 
      
Smoking history      
Never smoked 345 (68) 900 (76)  959 (73) 286 (74) 
Former smoker 30 (6) 95 (8)  97 (7) 28 (7) 
Current smoker (< 10 years) 95 (19) 143 (12)  193 (15) 45 (12) 
Current smoker (> 10 years) 38 (7) 47 (4)  59 (5) 26 (7) 
      
Age at menarche      
     < 10 years 91 (18) 219 (18)  226 (17) 84 (22) 
      
Heavy menstrual bleeding      
     Ever had heavy gushing type bleeding 169 (33) 456 (38)  466 (36) 159 (41) 
      
Reproductive history      
Nulliparous or never pregnant 222 (44) 440 (37)  477 (36) 185 (48) 
1 birth 120 (24) 312 (26)  344 (26) 88 (23) 
2 births 74 (15) 239 (20)  246 (19) 67 (17) 
> 3 births 92 (18) 194 (16)  241 (18) 45 (12) 
      
Time since last birth      
     0-4 years 167 (33) 379 (32)  467 (36) 79 (21) 
     5-9 years 81 (16) 255 (22)  265 (20) 71 (18) 
     Nulliparous or > 10 years ago 260 (51) 551 (47)  576 (44) 235 (61) 
      
Depo-Provera history*      
     Never used Depo-Provera 301 (59) 672 (57)  715 (55) 258 (67) 
     Short/Past (< 24 months, > 8 years ago)  25 (5) 128 (11)  113 (9) 40 (10) 
     Long/Past (> 24 months, > 8 years ago) 16 (3) 43 (4)  47 (4) 12 (3) 
     Short/Recent(< 24 months, within 8 years) 74 (15) 184 (16)  214 (16) 44 (11) 
     Long/Recent (> 24 months, within 8 years) 92 (18) 157 (13)  219 (17) 30 (8) 
      
Implant and H-IUD history      
     Used > 24 months 28 (6) 85 (7)  93 (7) 20 (5) 
*Annual household income was missing for n=12 participants. Employment was missing for n=4 participants. 
Education was missing for n=1 participants. Time since Depo-Provera use was missing for n=1 participant. 
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Abbreviations: SELF, Study of Environment, Lifestyle, and Fibroids; COC, combined oral contraceptives; IQR, 
interquartile range; hrs, hours; wk, week; PhD, doctor of philosophy; kg/m2, kilograms per square meter; H-IUD, 




Table 6.2. Combined oral contraceptive utilization and baseline fibroid prevalence in 1,693 women who 




Prevalence Ratios (95% CI) 
 n (%) Age-Adjusted                         Fully Adjusted* 
  MVR IPW/SMR MVR 
Ever use     
     Never (N=508) 113 (22) Ref. Ref. Ref. 
     Ever (N=1,185) 272 (23) 0.91 (0.76, 1.11) 0.90 (0.74, 1.10)† 0.90 (0.75, 1.08) 
Age at first use (years)     
     < 17 (N=410) 90 (22) Ref. Ref. Ref. 
     > 17 (N=775) 182 (23) 1.05 (0.84, 1.31) 1.00 (0.80, 1.26) 0.98 (0.79, 1.22) 
Duration of use (years)     
      < 1 (N=345) 67 (19) Ref. Ref. Ref. 
     1-1.99 (N=208) 44 (21) 1.06 (0.76, 1.48) 0.91 (0.64, 1.28) 0.93 (0.67, 1.28) 
     2-4.99 (N=310) 81 (26) 1.28 (0.97, 1.70) 1.15 (0.86, 1.54) 1.18 (0.90, 1.55) 
     > 5 (N=322) 80 (25) 1.16 (0.87, 1.54) 0.88 (0.65, 1.21) 0.91 (0.68, 1.21) 
Time since last use (years)‡     
     Current user (N=277) 61 (22) Ref. Ref. Ref. 
     1-2 (N=178) 44 (25) 1.16 (0.83, 1.61) 1.45 (1.00, 2.10) 1.26 (0.92, 1.75) 
     3-4 (N=125) 30 (24) 1.10 (0.76, 1.60) 1.14 (0.73, 1.79) 1.10 (0.76, 1.59) 
     > 5 (N=572) 131 (23) 0.89 (0.68, 1.16) 1.13 (0.83, 1.53) 1.06 (0.81, 1.39) 
Characteristics of use‡§     
     Short/past (N=327) 71 (22) Ref. Ref. Ref. 
     Short/recent (N=209) 37 (18) 1.02 (0.71, 1.46) 0.96 (0.65, 1.42) 0.89 (0.62, 1.27) 
     Long/past (N=245) 60 (24) 1.06 (0.78, 1.42) 0.93 (0.67, 1.30) 0.97 (0.73, 1.30) 
     Long/recent (N=371) 98 (26) 1.32 (1.02, 1.72) 0.99 (0.73, 1.33) 1.07 (0.82, 1.39) 
*Weighted (IPW/SMR) or Adjusted (MVR) for age in years (continuous), age at menarche (<11 years), Depo-
Provera duration of and time since last use (never use, short/past, long/past, short/recent, long/recent), total 
implant and H-IUD duration of use (>24 months), time since last birth (<5 years, 5-9.99 years, >10 years and no 
birth), parity (nulliparous, 1-2 births, >3 births), BMI (>30, remaining values according to tertile), education 
(Bachelor’s degree or higher). Excludes n=1 participants for whom time since Depo-Provera use was missing. 
 
†The weighted estimate for Ever-use was weighted according to the covariate distribution of COC users; i.e., 
standardized mortality ratio [SMR] weighting was employed for this exposure. 
 
‡Excludes n=33 participants who used both pill and mini-pill, for whom time since last COC use could not be 
distinguished. 
 
§Duration of use was characterized as short (< 2 years) or long (> 2 years). Time since last use was characterized 
as recent (< 5 years) or past (> 5 years). 
 
Abbreviations: SELF, Study of Environment, Lifestyle, and Fibroids; CI, confidence interval; MVR, multivariable 
logistic regression; IPW, inverse probability weighting; SMR, standardized mortality ratio; H-IUD, hormonal 




Table 6.3. Combined oral contraceptive utilization and fibroid incidence in 1,308 fibroid-free women 




Risk Ratios (95% CI) 
 n (%) Age-Adjusted                         Fully Adjusted* 
  MVR IPW/SMR MVR 
Ever use     
     Never (N=395) 77 (23) Ref. Ref. Ref. 
     Ever (N=913) 144 (19) 0.77 (0.60, 0.99) 0.78 (0.60, 1.00)† 0.76 (0.60, 0.98) 
Age at first use (years)     
     < 17 (N=320) 42 (16) Ref. Ref. Ref. 
     > 17 (N=593) 102 (20) 1.25 (0.90, 1.74) 1.25 (0.89, 1.76) 1.20 (0.86, 1.67) 
Duration of use (years)     
      < 1 (N=278) 34 (14) Ref. Ref. Ref. 
     1-1.99 (N=164) 29 (22) 1.49 (0.95, 2.33) 1.49 (0.94, 2.38) 1.43 (0.92, 2.22) 
     2-4.99 (N=229) 34 (17) 1.18 (0.76, 1.82) 1.10 (0.69, 1.74) 1.11 (0.72, 1.70) 
     > 5 (N=242) 47 (22) 1.48 (0.99, 2.21) 1.30 (0.83, 2.04) 1.23 (0.81, 1.86) 
Time since last use (years)‡     
     Current user (N=216) 36 (20) Ref. Ref. Ref. 
     1-2 (N=134) 25 (23) 1.18 (0.75, 1.85) 1.23 (0.72, 2.10) 1.23 (0.79, 1.92) 
     3-4 (N=95) 16 (19) 1.01 (0.60, 1.70) 0.96 (0.50, 1.85) 1.09 (0.64, 1.84) 
     > 5 (N=441) 64 (17) 0.77 (0.53, 1.12) 0.87 (0.55, 1.37) 0.91 (0.62, 1.33) 
Characteristics of use‡§     
     Short/past (N=256) 37 (17) Ref. Ref. Ref. 
     Short/recent (N=172) 25 (18) 1.25 (0.78, 2.00) 0.97 (0.58, 1.62) 1.09 (0.68, 1.74) 
     Long/past (N=185) 27 (17) 0.96 (0.61, 1.51) 0.92 (0.55, 1.54) 0.86 (0.55, 1.35) 
     Long/recent (N=273) 52 (22) 1.39 (0.95, 2.04) 1.19 (0.77, 1.83) 1.13 (0.76, 1.68) 
*Weighted (IPW/SMR) or Adjusted (MVR) for age in years (continuous), age at menarche (<11 years), Depo-
Provera duration of and time since last use (never use, short/past, long/past, short/recent, long/recent), total 
implant and H-IUD duration of use (>24 months), time since last birth (<5 years, 5-9.99 years, >10 years and no 
birth), parity (nulliparous, 1-2 births, >3 births), BMI (>30, remaining values according to tertile), education 
(Bachelor’s degree or higher).  
 
A total of n=198 women in SELF were censored, including n=136 COC users. Inverse probability of censoring 
weights were applied to upweight individuals most likely to have been censored who remained in the study. The 
model for probability of censoring included the exposure of interest (e.g., duration of use), all covariates used in 
the IPW/SMR models, with the addition of annual household income, baseline employment status, smoking 
history, and history of heavy gushing type bleeding.  
 
Annual household income was missing for n=12 participants. Education was missing for n=1 participants. Time 
since Depo-Provera use was missing for n=1 participant. 
 
†The weighted estimate for Ever-use was weighted according to the covariate distribution of COC users; i.e., 
standardized mortality ratio [SMR] weighting was employed for this exposure. 
 
‡Excludes n=33 participants who used both pill and mini-pill, for whom time since last COC use could not be 
distinguished. 
 
§Duration of use was characterized as short (< 2 years) or long (> 2 years). Time since last use was characterized 
as recent (< 5 years) or past (> 5 years). 
 
Abbreviations: SELF, Study of Environment, Lifestyle, and Fibroids; CI, confidence interval; MVR, multivariable 
logistic regression; IPW, inverse probability weighting; SMR, standardized mortality ratio; H-IUD, hormonal 
intrauterine device; BMI, body mass index. 
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Figure 6.1. IPW/SMR* associations between levels of combined oral 
contraceptive utilization and baseline fibroid prevalence among 1,683 women who 




*Weighted (IPW/SMR) or Adjusted (MVR) for age in years (continuous), age at menarche (<11 
years), Depo-Provera duration of and time since last use (never use, short/past, long/past, 
short/recent, long/recent), total implant and H-IUD duration of use (>24 months), time since last 
birth (<5 years, 5-9.99 years, >10 years and no birth), parity (nulliparous, 1-2 births, >3 births), 
BMI (>30, remaining values according to tertile), education (Bachelor’s degree or higher). 
Excludes n=1 participants for whom time since Depo-Provera use was missing. 
 
†The weighted estimate for Ever-use was weighted according to the covariate distribution of 
COC users; i.e., standardized mortality ratio [SMR] weighting was employed for this exposure. 
 
‡Excludes n=33 participants who used both pill and mini-pill, for whom time since last COC use 
could not be distinguished. 
 
§Duration of use was characterized as short (< 2 years) or long (> 2 years). Time since last use 
was characterized as recent (< 5 years) or past (> 5 years). 
 
Abbreviations: IPW, inverse probability weighting; SMR, standardized mortality ratio; SELF, 
Study of Environment, Lifestyle, and Fibroids; CI, confidence interval; MVR, multivariable logistic 
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Figure 6.2. IPW/SMR* associations between levels of combined oral 
contraceptive utilization and fibroid incidence among 1,308 fibroid-free women 




*Weighted (IPW/SMR) or Adjusted (MVR) for age in years (continuous), age at menarche (<11 
years), Depo-Provera duration of and time since last use (never use, short/past, long/past, 
short/recent, long/recent), total implant and H-IUD duration of use (>24 months), time since last 
birth (<5 years, 5-9.99 years, >10 years and no birth), parity (nulliparous, 1-2 births, >3 births), 
BMI (>30, remaining values according to tertile), education (Bachelor’s degree or higher).  
 
A total of n=198 women in SELF were censored, including n=136 COC users. Inverse probability 
of censoring weights were applied to upweight individuals most likely to have been censored 
who remained in the study. The model for probability of censoring included the exposure of 
interest (e.g., duration of use), all covariates used in the IPW/SMR models, with the addition of 
annual household income, baseline employment status, smoking history, and history of heavy 
gushing type bleeding.  
 
Annual household income was missing for n=12 participants. Education was missing for n=1 
participants. Time since Depo-Provera use was missing for n=1 participant. 
 
†The weighted estimate for Ever-use was weighted according to the covariate distribution of 
COC users; i.e., standardized mortality ratio [SMR] weighting was employed for this exposure. 
 
‡Excludes n=33 participants who used both pill and mini-pill, for whom time since last COC use 
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2.000.50
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§Duration of use was characterized as short (< 2 years) or long (> 2 years). Time since last use 
was characterized as recent (< 5 years) or past (> 5 years). 
 
Abbreviations: IPW, inverse probability weighting; SMR, standardized mortality ratio; SELF, 
Study of Environment, Lifestyle, and Fibroids; CI, confidence interval; MVR, multivariable logistic 





CHAPTER 7: DISCUSSION 
 This study was the first to investigate the association between fibroids and COC use in a 
prospective ultrasound-based study specifically designed to discover risk factors for uterine fibroids. This 
was also the first study to apply propensity-scored based methods to the problem of COC use and 
fibroids. Further, through the Study of Environment, Lifestyle, and Fibroids (SELF), we had access to high 
quality outcome data, detailed self-reported exposure data, and rich covariate data.  
Our Aim 1 results revealed widespread HC utilization in this cohort, namely Depo-Provera utilization and 
extensive COC use. COCs were the most common HC type used, and were the most common first HC 
type used, even among women who began using HCs after all other types became available. Many 
women reported using COCs exclusively for relief from menstrual problems, including irregular bleeding 
and painful periods.  
Our Aim 2 findings revealed that COC use or HC use in general might be protective against 
uterine fibroids. We report this finding cautiously, as when comparing never to ever users of any 
substance, there is always the potential for unmeasured confounding and limited public health utility of 
such estimates. However, our ever-never comparisons utilized standardized mortality ratio (SMR) 
weighting, which estimates the effect of treatment in the treated population, which may be more useful 
than findings from conditional estimates (i.e., our study explicitly seeks the answer to “what if the COC 
users had used something different or nothing at all?”). We were unable to endorse a protective or 
harmful association for age at first use, duration of use, or time since last use, among COC users. 
Associations found in previous literature may have been driven by the “Never” comparator group that was 
used for all levels of COC use. Our findings for these exposures may have been null in part because we 
chose to restrict our comparisons to women who had ever used COCs – comparing each level of COC 
use to the lowest level of use among users. We felt that this approach would be less biased and more 




Our findings should be considered in light of our study’s limitations. First, we did not have 
adequate statistical power to rule out small associations.76 The estimates reported are measures of 
association from a single cohort study and should be considered in context of a broader literature base. 
Second, all exposure and covariate data with the exception of BMI were self-reported. Self-reported 
history of OC use, as collected by telephone interview, has been found to be reliable when compared to 
automated pharmacy dispensing data.61 Third, we did not have exact duration of use estimates for COCs 
or H-IUDs and had to use limited available information to estimate duration of use for these HC types. 
Finally, women with prior clinical diagnosis were excluded from participating in SELF. While exclusion of 
women with clinical diagnosis of fibroids may have resulted in selection bias, only 5.87% (95% CI: 4.32, 
7.42) of U.S. black women aged 23-35 in 2011-2013 had ever been diagnosed with uterine fibroids, and 
the possible selection bias is expected to be small (unpublished analysis).77–79  
Our Aim 1 findings have the following, additional limitations. Reasons for HC use were self-
reported, and women’s definitions of heavy bleeding or irregular periods may vary. The data in our Aim 1 
analyses were exclusively cross-sectional. All Aim 1 analyses relied on retrospectively recalled data, 
including the incidence figures for HC initiation and menarche.  
Strengths 
This study has several strengths. Ours was the first prospective, ultrasound-based study to 
examine the association between COC use and uterine fibroids in young, black women. SELF performed 
ultrasounds in all study participants, including at baseline and follow-up, regardless of symptoms or health 
care access. Incidence analyses were restricted to women without fibroids at baseline, strengthening the 
temporality75 basis of our observed associations.  
Use or propensity score (PS) based methods allowed for greater transparency and interpretability 
of our findings. We are the first study to examine COC use and uterine fibroid outcomes using PS-based 
methods. Prior studies used multivariable regression models and most often compared different levels of 
COC user to never users, which may not be the most relevant comparison, as women are unlikely to 
choose between a specific level of COC use (e.g., duration of use 3-4 years) and never using COCs at 
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all. Analogous to the counterfactual conundrum of smoking, we are unlikely to ever live in a world in which 
no women ever use COCs. Therefore, our within-COC users comparisons are likely to be more relevant 
to prescribers, patients, and policymakers.   
Our Aim 1 analyses also had several strengths. First, we were able to assess HC use in a cohort 
of young, black women who came of age as five new HC options came to market: the implant, Depo-
Provera, H-IUDs, the ring, and the patch. Second, we examined uptake of these new methods relative to 
contextual and individual factors: regulatory approval and menarche, respectively. Third, to our 
knowledge, we were the first to examine temporal sequencing of HC use, and to find that COCs are the 
most common first HC among women who use multiple HC types, even among those initiating HC use 
well after other types became available. Fourth, our examination of reasons for use was specific to each 
HC type, and participants could report multiple reasons for use for each type. Finally, we compared our 
findings to unpublished NSFG analyses, and considered the potential for selection bias. Given the 
similarity of our findings to national estimates, our findings are likely generalizable to the broader 
population of U.S. black women of similar age. 
Public Health Implications 
In this study of 1,693 young, black women living in Detroit, we found that ever use of COCs might 
be protective against uterine fibroids when compared to use of no hormonal contraceptives (HCs) at all. 
This protective association disappeared when comparing COC users to ever-users of any other HC type, 
suggesting that HCs, and not necessarily COCs, may be protective against uterine fibroids. The findings 
from Aim 2 contribute to the evidence base for oral contraceptive safety and effectiveness, allowing 
providers and patients to make better, evidence-based decisions regarding oral contraception in women 
with or without fibroids.  
The emphasis of most public health research and interventions regarding HCs to date has been 
on pregnancy prevention. Our Aim 1 finding that a sizeable proportion of women used HCs for non-
contraceptive purposes are reinforced by prior, nationally representative findings 11 and point to HCs as 




Further research could explore clinical factors and patient preferences and values underlying HC 
selection, particularly for non-contraceptive purposes. If any HC use, and not necessarily COC use is 
protective against fibroids, then an additional non-contraceptive reason for HC use may become 
emergent. It is unclear how specific HC types compare to each other in terms of fibroid prevention, or how 
differing levels of COC use among COC users might confer differing levels of protection or harm, if any. 
Further studies are warranted in larger cohorts that would lead to estimates that are more precise and 
that build upon the methodological improvements represented by this study.   
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Appendix 1.1. Additional Methods 
Figure 5.1. We used the following formula for the standard errors to construct confidence bands: 
SE = sqrt(p*(1-p)/n). Where n is number in denominator for the proportion (i.e., number of women who 
had reached menarche by that year and had not yet initiated that HC type). 
Figure 5.3. We used the following formula for the standard errors to construct confidence bands: 
SE = sqrt(p*(1-p)/n). Where n is number in denominator for the proportion (in this case 1,693 women).   
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Appendix 1.2. Figure 5.3 (Age Time Scale)  
Figure 1.2. Cumulative incidence curves (with 95% CIs) for menarche and HC/EC initiation, by year, in 




Appendix 1.3. Figure 5.3 (Non-Cumulative) 
Figure 1.3. Number of women reaching menarche and initiating first HC or EC use, by year, in 1,693 
women who enrolled in SELF in 2010-2013 (Detroit, MI, USA)*† 
 
*HC initiation counts in this figure include emergency contraception (n=82, 5.5% of depicted initiations).  
 
†Excludes n=5 women who reported HC initiation prior to menarche and n=1 individual for whom age at first HC 
use was missing.  
 
Abbreviations: EC, emergency contraception; HC, hormonal contraceptive; SELF, Study of Environment, 
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Appendix 1.4. Results Stratified by Time between Menarche and SELF Enrollment 
Figures 1.4.(1-3). Sankey Diagram Stratified by Length of Observation Period (Time between Menarche 
and Cohort Entry) 
1. Window 1 (1-9 years) 
 
2. Window 2 (10-19 years) 
 




Tables 1.4.(1-5). Select Variables Stratified by Length of Observation Period (Time between Menarche 
and Cohort Entry) 
1. Number of HCs used (Continuous) 
Years between menarche and 
enrollment  N Minimum 
Lower 
Quartile Mean Median 
Upper 
Quartile Maximum 
0-9 years   36 1.0 1.0 1.5 1.0 2.0 3.0 
10-19 years   997 1.0 1.0 1.9 2.0 2.0 6.0 
20+ years   422 1.0 1.0 1.9 2.0 2.0 6.0 
 
2. Number of HCs used (Categorical) 
n (%) 1 HC Type 2 HC Types 3+ HC Types 
0-9 years menarche to baseline (n=36) 21 (58) 12 (33) 3 (8) 
10-19 years menarche to baseline (n=997) 417 (42) 345 (35) 235 (24) 
20+ years menarche to baseline (n=422) 172 (41) 150 (36) 100 (24) 
 
3. Duration of HC use in years (Continuous) 
Years between menarche and 
enrollment  N Minimum 
Lower 
Quartile Mean Median 
Upper 
Quartile Maximum 
0-9 years   36 0 1.0 2.9 2.0 4.0 10.0 
10-19 years   997 0 1.0 4.4 4.0 7.0 19.0 
20+ years   422 0 2.0 5.9 5.0 9.0 19.0 
 
4. Duration of HC use in years (Categorical) 
n (%) < 3 y 3-4 y 5-6 y 7-8 y > 8 y 
0-9 years menarche to baseline (n=36) 20 (56) 10 (28) 2 (6) 2 (6) 2 (6) 
10-19 years menarche to baseline (n=996) 393 (39) 182 (18) 157 (16) 109 (11) 155 (16) 
20+ years menarche to baseline (n=420) 128 (30) 61 (15) 60 (14) 52 (12) 119 (28) 
 
5. Reasons for HC use (Total) 
n (%) Birth Control Irregular Cycles Heavy Bleeding Menstrual Pain 
0-9 years menarche to baseline (n=36) 29 (81) 19 (53) 8 (22) 6 (17) 
10-19 years menarche to baseline (n=997) 929 (93) 408 (41) 218 (22) 168 (17) 
20+ years menarche to baseline (n=422) 399 (95) 160 (38) 97 (23) 81 (19) 
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Appendix 1.5. Sankey Diagrams Stratified by Menarche Decade 
Figures 1.5.(1-3). Sankey Diagrams Stratified by Menarche Decade 
1. Menarche Before 1990 
 
2. Menarche 1990-1999 
 




Appendix 1.6. NSFG Data Analyses, Supplement to Discussion 
Data 
Using publicly available data from the 2011-2013 National Survey for Family Growth (NSFG), in 
which women were asked whether they had ever been diagnosed with uterine fibroids, we  produced 
national estimates for ever fibroid diagnosis among black women in the same age range as our cohort. 
We found that 5.87%  (95% CI: 4.32, 7.42) of U.S. black women aged 23-35 in 2011-2013 had ever been 
diagnosed with uterine fibroids. With these same data, we also produced national estimates of current HC 
use by type in black women in this age range.  
Using both existing, published NSFG estimates and our age- and race- specific NSFG estimates, 
we compared NSFG findings for ever- and current HC use in SELF and U.S. black women in the same 
age range. In SELF, 86% of participants had ever used HCs and 70% had used COCs. In the 2006-2010 
NSFG, 86% of black women aged 15-44 had ever used HCs and 78% had used OCs [3]. Prevalences of 
current use at baseline for each HC type in SELF were similar to current use among black women of the 
same age (23-35 years) in the 2011-2013 NSFG (unpublished analyses), with Depo-Provera use slightly 
higher in the SELF cohort than in the NSFG (6% vs. 3%).   
Comment 
The generalizability of our findings should be considered in the context of the selection criteria of 
SELF, principally the age range, geographic location and the exclusion of women with clinically 
diagnosed fibroids.  
While exclusion of women with clinical diagnosis of fibroids may have resulted in selection bias, 
only 5.87% (95% CI: 4.32, 7.42) of U.S. black women aged 23-35 in 2011-2013 had ever been diagnosed 
with uterine fibroids, and the possible selection bias is expected to be small. Inclusion of these women 
would most likely have strengthened our findings, namely that COCs were the most common HC type 
used, most often the first HC type used, and that menstrual problems were a common reason for HC use 
– as COCs are a common first-line treatment for symptomatic uterine fibroids 23.  
With respect to the generalizability given the age range and geographic location of the SELF 
participants, we found that overall prevalences of HC and COC use in our cohort were similar to national 
estimates for reproductive aged black women. Given the similarity of the overall prevalences of HC use to 
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national estimates, our main findings are likely generalizable to the broader population of U.S. black 
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Appendix 2.1. Inclusion and exclusion flow diagrams for incidence analyses 
Figure 2.1.1. Flow diagram for the analysis of the association between ever COC use and incident 




“Skipped” F1/F2 ultrasounds may indicate uterine surgery (n=0 visits), censoring due to hysterectomy (n=11 visits), 
or missing ultrasound data due to pregnancy or other reasons (n=24 visits). 
 
Key: Oval, start; Pill, terminator (denotes final decision to include or exclude); Rectangle, process; Diamond, 
decision point.  
 
Abbreviations: SELF, Study of Environment, Lifestyle, and Fibroids; F1, first follow-up ultrasound (~20 months); 
F2, second follow-up ultrasound (~40 months). 
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Appendix 2.1. Inclusion and exclusion flow diagrams for incidence analyses (cont’d) 
Figure 2.1.2. Flow diagram for the analysis of the association of levels of COC use and incident 




“Skipped” F1/F2 ultrasounds may indicate uterine surgery (n=0 visits), censoring due to hysterectomy (n=8 visits), 
or missing ultrasound data due to pregnancy or other difficulties visualizing the uterus (n=18 visits). 
 
Key: Oval, start; Pill, terminator (denotes final decision to include or exclude); Rectangle, process; Diamond, 
decision point.  
 
Abbreviations: SELF, Study of Environment, Lifestyle, and Fibroids; F1, first follow-up ultrasound (~20 months); 
F2, second follow-up ultrasound (~40 months). 
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Appendix 2.2. Detailed Description of Propensity Score Based Methods 
Variable selection for PS model 
Substantive knowledge and directed acyclic graphs (DAGs) were used to determine which 
covariates to place into the propensity score and censoring models. Two experienced fibroid 
epidemiologists (DBB & QH) and one practicing OB/GYN (WKN) were consulted. 
Propensity score estimation 
Propensity scores were estimated by logistic regression and multinomial logistic regression for 
binary and non-binary exposures, respectively.80,81 The following variables were included in all propensity 
score models: age in years (continuous), age at menarche (<11 years), Depo-Provera duration of and 
time since last use (never use, short/past, long/past, short/recent, long/recent), total implant and H-IUD 
duration of use (>24 months), time since last birth (<5 years, 5-9.99 years, >10 years and no birth), parity 
(nulliparous, 1-2 births, >3 births), BMI (>30, and remaining values were divided into tertiles specific to 
each analysis, as described in Chapter 4), and education (Bachelor’s degree or higher).  
Censoring weights estimation 
The probability of remaining in the study conditional on covariates was estimated by logistic 
regression. For each model, we included the exposure of interest, all covariates used to estimate the PS 
for the exposure of interest, and annual household income (<$20,000, $20,000-49,999, and >$50,000 ), 
baseline employment status (not employed, employed <30 hours per week, employed >30 hours per 
week), smoking history (never smoked, former smoker, current smoker of <10 years, current smoker of 
>10 years) and history of heavy “gushing” type menstrual bleeding (yes/no). 
Applying the PS method: PS weighting 
Inverse probability (IP) weights were constructed for all exposures, and censoring. Standardized 
mortality ratio (SMR) type (see Chapter 4) weights were constructed for COC use. Use of weighting 
methods provided for clearer interpretation of findings, and the ability to intentionally define the 
hypothetical comparisons being made (i.e., average effect in the treated [ATT] versus average treatment 
effect [ATE]). These weights were easily combined with weights for missing outcomes.  
For incidence analyses, the IP and SMR weights were multiplied by the inverse probability of 
censoring weights. The range (mean, max, min) of unstabilized and stabilized weights are available in 
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Appendix 2.3 for prevalence models and 2.4 for incidence models. Weights were not truncated. Covariate 
balance tables appear in Appendix 2.5 for prevalence models and 2.6 for incidence models. 
Balance assessment 
Absolute standardized differences (ASD) were used to assess covariate balance with an a priori 
threshold of 0.1. Propensity score distributions were examined before and after weighting to assess for 
positivity and covariate balance, respectively. Stabilized weights did not confer any benefit in terms of 
covariate balance, as ASDs were lower for the non-stabilized weights. Since stabilized and unstabilized 
weights inherently produce the same point estimates and confidence intervals when the final, weighted 
model is saturated (see Hernán & Robins, 2016, section 12.3, page 16), we report the covariate balance 
and findings for the unstabilized weights.82 
Treatment effect estimation 
Weighted log-binomial regression models were used to estimate prevalence ratios and risk ratios 
for uterine fibroids. No additional covariates were included in the weighted models. Confidence intervals 
for weighted models were generated using robust variance (“sandwich”) estimator by use of the SAS 
REPEAT statement. Multivariable log-binomial regression models with the same covariates as used in the 
propensity score models were run for comparison. Sensitivity analyses were carried out to examine the 
potential influence of pregnancy and Depo-Provera use during follow-up on our findings. Multi-level 
outcome models were implemented with pregnancy and uterine fibroid incidence as a single joint 
outcome. To achieve this, we ran multinomial generalized logit models with robust variance estimation in 
PROC GEE. In a separate analysis, we added parity and Depo-Provera use during follow-up (as separate 
binary variables) to the IP and censoring weighted incidence models. Additionally, we examined fibroid 
incidence at 20-months in a multivariable logistic regression model. Finally, we re-defined the “Never” 
COC users group (in the prevalent and incident analyses for “Ever” COC use) to include only ever-HC 
users or only never-HC users to better understand how the composition of the “Never” group influenced 
our findings. 
Interpretation of effect estimates 
The prevalence and risk ratios computed for age at first COC use, duration of use, time since last 
use, and joint duration of and time since last use represent contrasts analogous to the average treatment 
89 
effect (ATE), i.e., the weights balance the covariate distribution to reflect the distribution among all COC 
users across all levels of COC use. For each comparison made, the corresponding counterfactual 
comparison to our weighted analysis was, “if the entire sample of COC users had used at this level versus 
the referent level.” The prevalence and risk ratios computed for ever-use of COCs represent contrasts 
analogous to the average effect in the treated (ATT), i.e., the weights balance the covariate distribution to 
reflect the distribution among COC users (i.e., the “treated” group). The relevant counterfactual 
comparison to our weighted analysis was, “if all COC users had not used COCs.” 
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Appendix 2.3. Sample Sizes and Mean Weights for Prevalence Models 
Table 2.3. Sample Sizes and Mean Weights for Prevalence Models 
 Age-adjusted Fully adjusted   
Model MVR IPW/SMR MVR IPW S_IPW/SMRW 
 N N N Mean [Range] Mean [Range] 
Ever use 1,693 1,691* 1,691 NA 1.40 [1.00, 7.00]* 
Age at first use 1,185 1,184 1,184 2.00 [1.19, 6.23] 1.00 [0.64, 2.15] 
Duration of use 1,185 1,184 1,184 4.01 [1.67, 21.25] 1.00 [0.45, 5.77] 
Time since last use 1,152 1,151 1,151 4.04 [1.11, 45.31] 1.00 [0.31, 9.86] 
Characteristics of use 1,152 1,151 1,151 4.01 [1.58, 22.58] 1.00 [0.39, 6.50] 
*SMR weights 
 
Abbreviations: MVR, multivariable regression; IPW, unstabilized inverse probability weighted; S_IPW, stabilized 






Appendix 2.4. Sample Sizes and Mean Weights for Incidence Models 
Table 2.4. Sample Sizes and Mean Weights for Incidence Models 
       
 
Age-
adjusted              Fully adjusted 
 
   
Model MVR IPW/SMR** MVR IPW S_IPW/SMRW Censoring weight Final weight** 
 N N N Mean [Range] Mean [Range] Mean [Range] Mean [Range] 
Ever use 1,110 1,098* 1,109 NA 1.39 [0.91, 6.37]* 1.00 [0.89, 1.33] 1.39 [0.87, 6.81]* 
Age at first use 777 769 777 1.99 [1.18, 6.49] 1.00 [0.66, 2.27] 1.00 [0.87, 1.49] 1.98 [1.11, 6.58] 
Duration of use 777 769 777 4.00 [1.65, 21.04] 1.00 [0.44, 5.58] 1.00 [0.88, 1.42] 3.99 [1.51, 22.89] 
Time since last use 754 747 754 4.06 [1.09, 45.72] 1.01 [0.27, 8.79] 1.00 [0.89, 1.39] 4.04 [1.03, 43.83] 
Characteristics of use 754 747 754 3.95 [1.49, 21.34] 0.99 [0.40, 5.75] 1.00 [0.88, 1.40] 3.93 [1.43, 21.23] 
*SMR weights 
**Includes censoring weights. For Ever use, final weights consisted of SMR multiplied by the censoring weight. For all other exposures, final weight consisted of 
IPW multiplied by censoring weight. 
 
Abbreviations: MVR, multivariable regression; IPW, unstabilized inverse probability weighted; SMR(W), standardized mortality ratio (weighted); S_IPW, 







Appendix 2.5. Covariate Balance & Propensity Score Curves for Prevalence Models 
Exposure 1: Ever used COCs 
Table 2.5.1. Covariate balance before and after SMR weighting for Ever/Never COC use among 1,696 SELF 
participants*† 
 Unweighted  SMR Weighted 
Variable Name Never COCs Ever COCs ASD  Never COCs Ever COCs ASD 
Age at enrollment 27.99  29.06  0.31   29.06  29.06    0.00  
BMI category 2.16  2.21  0.04     2.22    2.21    0.01  
Depo-Provera use  1.27  1.18  0.06     1.18    1.18    0.00  
H-IUD/Implant use 0.06  0.07  0.07     0.08    0.07    0.01  
Bachelor’s degree  0.22  0.31  0.21     0.31    0.31    0.01  
Menarche age < 11 yrs. 0.18  0.18  0.02     0.18    0.19    0.01  
Parity category 1.07  1.16  0.08     1.17    1.16    0.01  
Time since last birth  1.18  1.15  0.04     1.12    1.15    0.02  
 
Abbreviations: ASD, absolute standardized difference; BMI, body mass index; COCs, combined oral contraceptives; H-
IUD, hormonal intrauterine device; SELF, study of environment lifestyle and fibroids; SMR, standardized mortality ratio. 
 
Figure 2.5.1. Unweighted & weighted PS distributions for Ever/Never Prevalence SMR weighted model. 
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Appendix 2.5. Covariate Balance & Propensity Score Curves for Prevalence Models (Cont’d) 
Exposure 2: Age at first COC use 
Table 2.5.2. Covariate balance before and after IP weighting for Age at first COC use among 1,696 SELF 
participants*† 
 Unweighted  IP Weighted 
Variable Name 
AFU < 17 
years 
AFU > 17 
years ASD  
AFU < 17 
years 
AFU > 17 
years ASD 
Age at enrollment 29.03  29.08  0.01   29.08  29.05  0.00  
BMI category 2.30  2.14  0.14   2.19  2.19  0.00  
Depo-Provera use  1.34  1.09  0.17   1.19  1.18  0.00  
H-IUD/Implant use 0.07  0.07  0.04   0.08  0.07  0.01  
Bachelor’s degree  0.23  0.35  0.27   0.31  0.31  0.00  
Menarche age < 11 yrs. 0.20  0.18  0.06   0.18  0.18  0.00  
Parity category 1.27  1.10  0.15   1.15  1.15  0.00  
Time since last birth  1.13  1.15  0.03   1.13  1.14  0.01  
 
Abbreviations: AFU, age at first use; ASD, absolute standardized difference; BMI, body mass index; COCs, combined 
oral contraceptives; H-IUD, hormonal intrauterine device; SELF, study of environment lifestyle and fibroids; IP, inverse 
probability. 
 
Figure 2.5.2. Unweighted & weighted PS distributions for Age at first COC use Prevalence IPW model. 
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Appendix 2.5. Covariate Balance & Propensity Score Curves for Prevalence Models (Cont’d) 
Exposure 3: Duration of COC use 
Table 2.5.3.a. Unweighted covariate balance table for Duration of COC use among 1,184 COC users in SELF*† 
Variable Name < 1 year (0) 1 - 1.99 years (1) 2 - 4.99 years (2) 5 + years (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment        28.54         29.12         28.87         29.75  0.17  0.10  0.36  
BMIcategory          2.21           2.10           2.19           2.24  0.10  0.02  0.03  
Depo-Provera use           1.45           1.26           1.25           0.75  0.11  0.12  0.47  
H-IUD/Implant use          0.10           0.08           0.05           0.06  0.05  0.15  0.15  
Bachelor’s degree          0.19           0.27           0.31           0.45  0.18  0.27  0.58  
Menarche age < 11 yrs.          0.20           0.17           0.18           0.19  0.08  0.06  0.03  
Parity category          1.34           1.19           1.16           0.93  0.13  0.16  0.38  
Time since last birth          1.01           1.16           1.18           1.25  0.18  0.20  0.28  
 
Table 2.5.3.b. IP weighted covariate balance table for Duration of COC use among 1,184 COC users in SELF*† 
Variable Name < 1 year (0) 1 - 1.99 years (1) 2 - 4.99 years (2) 5 + years (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment        29.04         29.12         29.06         29.00  0.01  0.00  0.01  
BMI category          2.21           2.19           2.20           2.19  0.01  0.00  0.01  
Depo-Provera use           1.18           1.19           1.17           1.22  0.00  0.00  0.02  
H-IUD/Implant use          0.08           0.07           0.07           0.09  0.01  0.01  0.02  
Bachelor’s degree          0.31           0.31           0.30           0.30  0.00  0.01  0.01  
Menarche age < 11 yrs.          0.19           0.19           0.18           0.19  0.01  0.01  0.00  
Parity category          1.13           1.15           1.16           1.15  0.01  0.01  0.01  
Time since last birth          1.17           1.15           1.13           1.14  0.01  0.02  0.02  
 
Abbreviations: ASD, absolute standardized difference; BMI, body mass index; COCs, combined oral contraceptives; H-
IUD, hormonal intrauterine device; IPW, inverse probability weighting; SELF, study of environment lifestyle and fibroids. 
 




0.0 0.2 0.4 0.6















DOU < 1 year
0.0 0.2 0.4 0.6















DOU < 1 year
95 
Appendix 2.5. Covariate Balance & Propensity Score Curves for Prevalence Models (Cont’d) 
Exposure 4: Time since last COC use 
Table 2.5.4.a. Unweighted covariate balance table for time since last COC use among 1,184 COC users 
in SELF 
Variable Name Current users (0) 1-2 years (1) 3-4 years (2) 5+ years (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment        28.26         28.06         28.03         29.99  0.06  0.06  0.53  
BMI category          2.12           2.19           2.21           2.23  0.06  0.08  0.10  
Depo-Provera use           0.77           1.33           0.91           1.38  0.38  0.10  0.41  
H-IUD/Implant use          0.05           0.04           0.10           0.09  0.04  0.22  0.16  
Bachelor’s degree          0.42           0.34           0.38           0.22  0.16  0.09  0.44  
Menarche age < 11 y          0.16           0.19           0.19           0.19  0.06  0.08  0.08  
Parity category          0.82           0.96           0.81           1.45  0.15  0.01  0.61  
Time since last birth          1.23           1.19           1.22           1.09  0.05  0.02  0.17  
 
Table 2.5.4.b. IP Weighted covariate balance table for time since last COC use among 1,184 COC users 
in SELF 
Variable Name Current users (0) 1-2 years (1) 3-4 years (2) 5+ years (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment        29.30         29.13         29.31         29.20  0.02  0.00  0.02  
BMI category          2.27           2.16           2.22           2.21  0.04  0.01  0.03  
Depo-Provera use           1.40           1.23           1.06           1.22  0.05  0.09  0.06  
H-IUD/Implant use          0.07           0.07           0.07           0.08  0.00  0.00  0.01  
Bachelor’s degree          0.29           0.30           0.33           0.29  0.01  0.03  0.01  
Menarche age < 11 y          0.17           0.18           0.20           0.19  0.00  0.03  0.02  
Parity category          1.21           1.13           1.15           1.16  0.03  0.02  0.02  
Time since last birth          1.17           1.18           1.17           1.15  0.00  0.00  0.01  
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Appendix 2.5. Covariate Balance & Propensity Score Curves for Prevalence Models (Cont’d) 
Exposure 5: Joint duration of and time since last COC use 
Table 2.5.5.a. Unweighted covariate balance table for joint duration of and time since last COC use 
among 1,184 COC users in SELF 
Variable Name Short/Past (0) Short/Recent (1) Long/Past (2) Long/Recent (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment        29.68         27.31         30.40         28.62  0.72  0.23  0.32  
BMI category          2.20           2.11           2.27           2.18  0.08  0.06  0.02  
Depo-Provera use           1.47           1.23           1.26           0.82  0.15  0.13  0.43  
H-IUD/Implant use          0.10           0.08           0.07           0.05  0.09  0.13  0.21  
Bachelor’s degree          0.17           0.30           0.28           0.44  0.29  0.25  0.59  
Menarche age < 11 y          0.20           0.17           0.18           0.18  0.09  0.05  0.05  
Parity category          1.50           0.93           1.39           0.82  0.52  0.10  0.64  
Time since last birth          1.03           1.12           1.16           1.27  0.10  0.14  0.27  
 
Table 2.5.5.b. IP Weighted covariate balance table for joint duration of and time since last COC use 
among 1,184 COC users in SELF 
Variable Name Short/Past (0) Short/Recent (1) Long/Past (2) Long/Recent (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment        29.19         29.31         29.23         29.19  0.02  0.01  0.00  
BMI category          2.22           2.14           2.24           2.21  0.03  0.01  0.01  
Depo-Provera use           1.19           1.29           1.28           1.25  0.03  0.03  0.02  
H-IUD/Implant use          0.08           0.07           0.07           0.07  0.01  0.00  0.01  
Bachelor’s degree          0.31           0.28           0.28           0.31  0.02  0.03  0.00  
Menarche age < 11 y          0.19           0.18           0.20           0.19  0.01  0.01  0.00  
Parity category          1.12           1.16           1.18           1.13  0.02  0.03  0.01  
Time since last birth          1.19           1.15           1.11           1.19  0.02  0.04  0.00  
 
Figure 2.5.5. Unweighted & weighted PS distributions for JOINT duration of and time since last COC use 
prevalence IP weighted model. 
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Appendix 2.6. Covariate Balance & Propensity Score Curves for Incidence Models 
Exposure 1: Ever used COCs 
Table 2.6.1. Covariate balance before and after SMR weighting for Ever/Never COC use among 1,308 SELF 
participants*† 
 Unweighted  SMR & Censoring Weighted 
Variable Name Never COCs Ever COCs ASD  Never COCs Ever COCs ASD 
Age at enrollment 27.57 28.73 0.34   28.65  28.75  0.02  
BMI category 2.11  2.21  0.09   2.20  2.21  0.01  
Depo-Provera use  1.41  1.28  0.08   1.30  1.26  0.02  
H-IUD/Implant use 0.06  0.07  0.04   0.08  0.07   0.01  
Bachelor’s degree  0.20  0.28  0.18   0.27  0.28   0.03  
Menarche age < 11 yrs. 0.16  0.18  0.03   0.17  0.17  0.00  
Parity category 1.13  1.22  0.08   1.25  1.21   0.03  
Time since last birth  1.12  1.07  0.06   1.01  1.08  0.06  
 
Abbreviations: ASD, absolute standardized difference; BMI, body mass index; COCs, combined oral 
contraceptives; H-IUD, hormonal intrauterine device; SELF, study of environment lifestyle and fibroids; SMR, 
standardized mortality ratio. 
 
Figure 2.6.1. Unweighted & weighted PS distributions for Ever/Never Incidence Censor/SMR weighted 
model. 
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Appendix 2.6. Covariate Balance & Propensity Score Curves for Incidence Models (Cont’d) 
Exposure 2: Age at first COC use 
Table 2.6.2. Covariate balance before and after IP weighting for Age at first COC use among 1,308 SELF 
participants*† 
 Unweighted  IP & Censoring Weighted 
Variable Name 
AFU < 17 
years 
AFU > 17 
years ASD  
AFU < 17 
years 
AFU > 17 
years ASD 
Age at enrollment 28.64  28.78  0.04   28.79  28.66    0.03  
BMI category 2.35  2.12  0.21     2.21    2.19    0.01  
Depo-Provera use  1.40  1.22  0.11     1.30    1.26    0.01  
H-IUD/Implant use 0.07  0.08  0.05     0.08    0.08    0.00  
Bachelor’s degree  0.21  0.32   0.26     0.28    0.28    0.01  
Menarche age < 11 yrs. 0.18  0.17   0.02     0.17    0.17        -    
Parity category 1.32  1.17   0.13     1.23    1.19    0.02  
Time since last birth  1.05  1.08  0.04     1.06    1.07    0.01  
 
Abbreviations: AFU, age at first use; ASD, absolute standardized difference; BMI, body mass index; COCs, combined 
oral contraceptives; H-IUD, hormonal intrauterine device; SELF, study of environment lifestyle and fibroids; IPW, inverse 
probability. 
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Appendix 2.6. Covariate Balance & Propensity Score Curves for Incidence Models (Cont’d) 
Exposure 3: Duration of COC use 
Table 2.6.3.a. Unweighted covariate balance table for Duration of COC use among 913 COC users in SELF*† 
Variable Name < 1 year (0) 1 - 1.99 years (1) 2 - 4.99 years (2) 5 + years (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment  28.27   28.63   28.67   29.38  0.10 0.12 0.33  
BMIcategory 2.19 2.14 2.23   2.24   0.04   0.04  0.05  
Depo-Provera use  1.56  1.37  1.36   0.83   0.12   0.12  0.48  
H-IUD/Implant use 0.09  0.09  0.05   0.06   0.01   0.16  0.12  
Bachelor’s degree 0.17  0.26  0.28   0.43   0.24   0.28  0.59  
Menarche age < 11 yrs. 0.19  0.18  0.16   0.17   0.04   0.09  0.06  
Parity category 1.43  1.20  1.25   0.96   0.20   0.16  0.44  
Time since last birth 0.92  1.10  1.11   1.17   0.21   0.23  0.29  
 
Table 2.6.3.b. IP and censoring weighted covariate balance table for Duration of COC use among 1,184 COC users 
in SELF*† 
Variable Name < 1 year (0) 1 - 1.99 years (1) 2 - 4.99 years (2) 5 + years (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment 28.67  28.67  28.67  28.76    0.00    0.00    0.01  
BMI category   2.22    2.19    2.21    2.21    0.02    0.01    0.01  
Depo-Provera use    1.25    1.31    1.31    1.37    0.02    0.02    0.04  
H-IUD/Implant use   0.08    0.08    0.07    0.10    0.00    0.03    0.04  
Bachelor’s degree   0.27    0.28    0.28    0.26    0.01    0.01    0.01  
Menarche age < 11 yrs.   0.17    0.18    0.18    0.19    0.01    0.01    0.03  
Parity category   1.17    1.26    1.20    1.27    0.04    0.01    0.05  
Time since last birth   1.12    1.05    1.06    1.02    0.04    0.04    0.06  
 
Abbreviations: ASD, absolute standardized difference; BMI, body mass index; COCs, combined oral contraceptives; H-
IUD, hormonal intrauterine device; IPW, inverse probability weighting; SELF, study of environment lifestyle and fibroids. 
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Appendix 2.6. Covariate Balance & Propensity Score Curves for Incidence Models (Cont’d) 
Exposure 4: Time since last COC use 
Table 2.6.4.a. Unweighted covariate balance for time since last COC use among 913 COC users who 
were fibroid-free at enrollment in SELF 
Variable Name Current users (0) 1-2 years (1) 3-4 years (2) 5+ years (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment 27.88  27.56  27.64  29.77  0.10  0.07  0.56  
BMI category 2.12  2.20  2.24  2.24  0.07  0.11  0.11  
Depo-Provera use  0.81  1.50  0.99  1.50  0.46  0.13  0.45  
H-IUD/Implant use 0.05  0.04  0.13  0.09  0.04  0.29  0.18  
Bachelor’s degree 0.38  0.32  0.29  0.20  0.11  0.17  0.38  
Menarche age < 11 y 0.14  0.16  0.19  0.19  0.06  0.12  0.13  
Parity category 0.88  0.99  0.84  1.53  0.11  0.04  0.62  
Time since last birth 1.17  1.12  1.16  0.99  0.06  0.01  0.20  
 
Table 2.6.4.b. Censoring Weighted and IPW Weighted covariate balance for time since last COC use 
among 913 COC users who were fibroid-free at enrollment in SELF 
Variable Name Current users (0) 1-2 years (1) 3-4 years (2) 5+ years (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment 29.09  28.51  29.23  28.89    0.07    0.01    0.03  
BMI category   2.32    2.20    2.20    2.23    0.05    0.04    0.04  
Depo-Provera use    1.49    1.33    1.25    1.29    0.04    0.06    0.07  
H-IUD/Implant use   0.08    0.10    0.07    0.08    0.02    0.03    0.01  
Bachelor’s degree   0.26    0.27    0.30    0.26    0.01    0.04    0.00  
Menarche age < 11 y   0.16    0.15    0.20    0.18    0.01    0.03    0.02  
Parity category   1.27    1.03    1.30    1.24    0.10*    0.01    0.01  
Time since last birth   1.14    1.16    1.02    1.07    0.01    0.05    0.05  
*0.09992 
 
Figure 2.6.4. Unweighted & weighted PS distributions for time since last COC use incidence 
Censoring/IP weighted model. 
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Appendix 2.6. Covariate Balance & Propensity Score Curves for Incidence Models (Cont’d) 
Exposure 5: Joint duration of and time since last COC use 
Table 2.6.5.a. Unweighted covariate balance for joint duration of and time since last COC use among 913 
COC users who were fibroid-free at enrollment in SELF 
Variable Name Short/Past (0) Short/Recent (1) Long/Past (2) Long/Recent (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment        29.45         26.88         30.21         28.27  0.78  0.24  0.35  
BMI category          2.20           2.14           2.30           2.19  0.05  0.10  0.00  
Depo-Provera use           1.61           1.28           1.34           0.91  0.20  0.17  0.45  
H-IUD/Implant use          0.11           0.08           0.07           0.05  0.08  0.12  0.22  
Bachelor’s degree          0.15           0.27           0.28           0.39  0.28  0.30  0.55  
Menarche age < 11 y          0.20           0.17           0.18           0.15  0.05  0.03  0.12  
Parity category          1.60           0.96           1.43           0.87  0.59  0.15  0.68  
Time since last birth          0.93           1.07           1.08           1.21  0.16  0.18  0.32  
 
Table 2.6.5.b Censoring Weighted and IPW Weighted covariate balance for joint duration of and time 
since last COC use among 913 COC users who were fibroid-free at enrollment in SELF 
Variable Name Short/Past (0) Short/Recent (1) Long/Past (2) Long/Recent (3) 
ASD  
1 vs. 0 
ASD  
2 vs. 0 
ASD  
3 vs. 0 
Age at enrollment 28.90  28.58  28.83  29.03    0.04    0.01    0.02  
BMI category   2.21    2.20    2.29    2.23    0.01    0.04    0.01  
Depo-Provera use    1.25    1.32    1.39    1.38    0.02    0.04    0.04  
H-IUD/Implant use   0.08    0.09    0.07    0.08    0.01    0.02    0.01  
Bachelor’s degree   0.26    0.30    0.26    0.27    0.04    0.01    0.01  
Menarche age < 11 y   0.18    0.16    0.18    0.19    0.03    0.00    0.01  
Parity category   1.21    1.11    1.24    1.19    0.04    0.02    0.01  
Time since last birth   1.11    1.15    1.01    1.13    0.03    0.05    0.01  
 
Figure 2.6.5. Unweighted & weighted PS distributions for JOINT duration of and time since last COC use 
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Appendix 2.7. Sensitivity Analyses 
Appendix 2.7.1. Incidence Models Taking Into Consideration Depo-Provera Use and Pregnancy 
During Follow-Up 
In these models, Depo-Provera use (>9 months duration) and parity (yes/no) during follow-up 
were added to the IPW and censoring weighted models, as well as the traditional log binomial regression 
models.  
Table 2.7.1. Incidence Models Taking Into Consideration Depo-Provera Use and Pregnancy during 
Follow-Up 
 MVR IP/SMR Weighted 
   
Ever use N=1,096 N=1,085 
     Never (N=395) Ref. Ref. 
     Ever (N=913) 0.76 (0.59, 0.99) 0.79 (0.60, 1.03) 
Age at first use (years) N=769 N=761 
     < 17 (N=320) Ref. Ref. 
     > 17 (N=593) 1.22 (0.87, 1.72) 1.29 (0.91, 1.84) 
Duration of use (years) N=769 N=761 
      < 1 (N=278) Ref. Ref. 
     1-1.99 (N=164) 1.39 (0.89, 2.18) 1.43 (0.88, 2.31) 
     2-4.99 (N=229) 1.06 (0.68, 1.65) 1.04 (0.64, 1.67) 
     > 5 (N=242) 1.16 (0.76, 1.78) 1.21 (0.76, 1.93) 
Time since last use (years) N=746 N=739 
     Current user (N=216) Ref. Ref. 
     1-2 (N=134) 1.15 (0.72, 1.84) 1.10 (0.63, 1.91) 
     3-4 (N=95) 1.07 (0.62, 1.83) 0.95 (0.49, 1.84) 
     > 5 (N=441) 0.84 (0.57, 1.25) 0.77 (0.47, 1.28) 
Characteristics of use N=746 N=739 
     Short/past (N=256) Ref. Ref. 
     Short/recent (N=172) 1.13 (0.69, 1.85) 0.92 (0.53, 1.59) 
     Long/past (N=185) 0.82 (0.51, 1.30) 0.83 (0.49, 1.41) 




Appendix 2.7. Sensitivity Analyses (Cont’d) 
Appendix 2.7.2. Mutli-Level Outcome Models for Parity during Follow-Up 
In this sensitivity analysis, multinomial generalized logit models with robust variance estimation 
were run in PROC GEE. These findings represent the main IPW/Censoring weighted models, with a 
multi-level outcome that takes into account parity during follow-up. 
Table 2.7.2. Mutli-Level Outcome Models for Parity during Follow-Up 
 Outcome IPW/SMR  
Odds Ratio 
95% CI  
Lower 
95% CI  
Upper 
Ever use versus never use (referent) 
 No fibroid, Births   0.89    0.52      1.50  
 Fibroid, No births   0.74    0.48      1.15  
 Fibroid & Births   0.66    0.25      1.74  
Age at first use <17 years versus <17 years (referent) 
 No fibroid, Births   1.03    0.53      2.02  
 Fibroid, No births   1.71    0.90      3.25  
 Fibroid & Births   0.47    0.11      2.00  
Duration of use 1-1.99 years versus <1 year (referent) 
 No fibroid, Births   0.98    0.28      3.44  
 Fibroid, No births   1.39    0.39      4.97  
 Fibroid & Births   3.98    0.20    80.95  
Duration of use 2-4.99 years versus <1 year (referent) 
 No fibroid, Births   0.72    0.21      2.49  
 Fibroid, No births   0.98    0.30      3.20  
 Fibroid & Births   1.44    0.06    33.00  
Duration of use >5 years versus <1 year (referent) 
 No fibroid, Births   0.81    0.16      4.16  
 Fibroid, No births   1.13    0.34      3.78  
 Fibroid & Births   1.99    0.08    46.46  
Time since last use 1-2 years versus <1 year (referent) 
 No fibroid, Births   0.69    0.08      5.71  
 Fibroid, No births   1.14    0.22      5.75  
 Fibroid & Births   0.42    0.01    17.31  
Time since last use 3-4 years versus <1 year (referent) 
 No fibroid, Births   1.34    0.14    12.62  
 Fibroid, No births   1.09    0.20      5.99  
 Fibroid & Births   0.19    0.00    32.53  
Time since last use >5 years versus <1 year (referent) 
 No fibroid, Births   0.57    0.08      4.04  
 Fibroid, No births   0.67    0.21      2.12  
 Fibroid & Births   0.66    0.02    20.76  
Long/Past versus Short/Past (referent) 
 No fibroid, Births   0.85    0.11      6.42  
 Fibroid, No births   0.73    0.19      2.85  
 Fibroid & Births   0.97    0.05    18.79  
Long/Recent versus Short/Past (referent) 
 No fibroid, Births   1.16    0.21      6.48  
 Fibroid, No births   1.29    0.35      4.68  
 Fibroid & Births   1.06    0.09    12.91  
Short/Recent versus Short/Past (referent) 
 No fibroid, Births   2.62    0.64    10.68  
 Fibroid, No births   1.15    0.29      4.64  
 Fibroid & Births   1.05    0.04    25.59  
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Appendix 2.7. Sensitivity Analyses (Cont’d) 
Appendix 2.7.3. Incidence Models for Fibroids at First Follow-Up (~20 months) 
Traditional log binomial regression models for fibroid status at first follow-up time point, using the 
same adjustment set as the main analyses. Censored individuals (n=198 SELF participants; n=136 COC 
users) were excluded from this sensitivity analysis. 
Table 2.7.3. Incidence Models for Fibroids at First Follow-Up (~20 months) 
 MVR Risk Ratio (95% CI) 
Ever use N=1,130 
     Never  Ref. 
     Ever  0.85 (0.58, 1.23) 
Age at first use  N=792 
     < 17 years Ref. 
     > 17 years 1.14 (0.72, 1.80) 
Duration of use  N=792 
      < 1 years Ref. 
     1-1.99 years 1.44 (0.74, 2.77) 
     2-4.99 years 1.46 (0.80, 2.64) 
     > 5 years 1.33 (0.73, 2.42) 
Time since last use N=767 
     Current user Ref. 
     1-2 years 0.87 (0.46, 1.67) 
     3-4 years 0.93 (0.47, 1.85) 
     > 5 years 0.62 (0.37, 1.02) 
Characteristics of use N=767 
     Short/past  Ref. 
     Short/recent  1.08 (0.54, 2.17) 
     Long/past  0.78 (0.41, 1.50) 
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